[go: up one dir, main page]

WO1996033717A1 - Therapeutic composition for arthritis - Google Patents

Therapeutic composition for arthritis Download PDF

Info

Publication number
WO1996033717A1
WO1996033717A1 PCT/JP1996/001102 JP9601102W WO9633717A1 WO 1996033717 A1 WO1996033717 A1 WO 1996033717A1 JP 9601102 W JP9601102 W JP 9601102W WO 9633717 A1 WO9633717 A1 WO 9633717A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazol
phenyl
benzenesulfonamide
pharmaceutical composition
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1996/001102
Other languages
French (fr)
Inventor
Haruhiko Makino
Takashi Sohda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to EP96912213A priority Critical patent/EP0830133A1/en
Priority to AU55136/96A priority patent/AU715358B2/en
Publication of WO1996033717A1 publication Critical patent/WO1996033717A1/en
Priority to NO974956A priority patent/NO974956D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Definitions

  • the present invention relates to a pharmaceutical composition that serves well as a therapeutic agent for arthritis, especially as an anti-rheumatic agent.
  • Rheumatoid arthritis also called chronic rheumatism
  • rheumatoid arthritis is a chronic multiple arthritis characterized by inflammatory changes in the synovial membrane of the articular capsule inner layer.
  • Arthritic diseases such as rheumatoid arthritis are progressive, and cause joint disorders such as deformation and acampsia, often resulting in severe physical disorder due to a lack of effective treatment and subsequent deterioration.
  • these forms of arthritis have been chemotherapeutically treated with various agents, including steroids such as cortisone and other adrenocortical hormones, non-steroidal anti-inflammatory agents such as aspirin, piroxicam and indomethacin, gold agents such as aurothiomalate, antirheumatic agents such as chloroquine preparations and D-penicillamine, anti-gout agents such as colchicine, and immunosuppressors such as cyclophosphamide, azathioprine, methotrexate and levamisole.
  • steroids such as cortisone and other adrenocortical hormones
  • non-steroidal anti-inflammatory agents such as aspirin, piroxicam and indomethacin
  • gold agents such as aurothiomalate
  • antirheumatic agents such as chloroquine preparations and D-penicillamine
  • anti-gout agents such as colchicine
  • immunosuppressors such as cyclopho
  • the present inventors found that excellent anti- inflammatory analgesic effect against chronic arthritis can be obtained from initial treatment, and sustained safely for an extended period of time, by administering a pharmaceutical comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent possessing acute inflammation-suppressing and analgesic activities, providing clinical effect in 30 minutes, in 2 to 3 days or at latest within 1 week, such as ⁇ a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid, or ® an anti-inflammatory enzyme agent.
  • the inventors conducted further investigation based on this finding, and developed the present invention.
  • the present invention relates to:
  • a pharmaceutical composition comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
  • Y represents a nitrogen atom or C-G (G represents a carboxyl group which may be esterified or amidated, an acyl, or a hydroxyalkyl group); R represents an optionally substituted hydrocarbon residue, or an optionally substituted heterocyclic group; X represents an oxygen atom or an optionally oxidized sulfur atom; n represents 0 or 1; k represents 0 or 1; G and R may bind together to form a ring; rings A and B may each have a substituent; or a pharmaceutically acceptable salt thereof.
  • a therapeutic agent for arthritis comprising a combination of a qunoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
  • a method of treating an arthritis and/or an inflammation in mammals which comprises administering to the mammals a therapeutically effective amount of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
  • Quinoline or quinazoline compound for the prophylaxis or therapy of arthritis useful for the present invention generically refer to the class of prophylactic/therapeutic agents for arthritis comprising compounds having a quinoline or quinazoline skeleton as an active ingredient.
  • These compounds and their production methods are described in detail, for instance, in Japanese Patent Unexamined Publication (Kokai tokkyo koho) Nos. 306052/1994(EP-A- 0567107), 118266/1995(EP-A-0608870), 69890/1995(EP-A- 0634169), 53419/1996(EP-A-0686630) and W095/24394.
  • Those compounds are practically represented by the above formula (I), all possess prophylactic/therapeutic activity against arthritis and are advantageously used for the present invention
  • the optionally substituted hydrocarbon residue for R is exemplified by aliphatic hydrocarbon residues, alicyclic hydrocarbon residues, alicyclic-aliphatic hydrocarbon residues, aromatic carbon ring-aliphatic hydrocarbon residues and aromatic hydrocarbon residues.
  • Such aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 8 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert- pentyl, hexyl, isohexyl, heptyl, octyl); and unsaturated aliphatic hydrocarbon residues having 2 to 8 carbon atoms (e.g., vinyl (ethenyl), 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l-propenyl, 1-pentenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1- hexenyl, 3-hexenyl, 2,4
  • Such alicyclic hydrocarbon residues include saturated alicyclic hydrocarbon residues having 3 to 7 carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl) ; and unsaturated alicyclic hydrocarbon residues having 5 to 7 carbon atoms (e.g., 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2- cycloheptenyl, 3-cycloheptenyl, 2,4-cycloheptadienyl) .
  • saturated alicyclic hydrocarbon residues having 3 to 7 carbon atoms e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl
  • Such alicyclic-aliphatic hydrocarbon residues include those comprising a combination of C 4 - 9 one of the above- mentioned alicyclic hydrocarbon residues and one of the above-mentioned aliphatic hydrocarbon residues (e.g., cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3- cyclopentenylmethyl, cyclohexylmethyl, 2- cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, cycloheptylethyl) .
  • aromatic carbon ring-aliphatic hydrocarbon residues include phenylalkyls having 7 to 9 carbon atoms (e.g., benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2- phenylpropyl, 1-phenylpropyl); and naphthylalkyls having 11 to 13 carbon atoms (e.g., ⁇ -naphthylmethyl, ⁇ -naphthylethyl, ?-naphthylmethyl and /?-naphthylethyl) .
  • aromatic hydrocarbon residues include phenyl and naphthyl (e.g., ⁇ -naphthyl, /?-naphthyl) .
  • the optionally substituted hydrocarbon residue for R is preferably a group represented by the formula: -CH -X 1 -Z 1 wherein X 1 represents an oxygen atom, an optionally oxidized sulfur atom, or -(CH 2 ) m ⁇ (m represents an integer from 0 to 5); Z 1 represents an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group, or an optionally substituted amino group.
  • the optionally oxidized sulfur atom for X 1 is exemplified by the thio group, sulfinyl group and sulfonyl group, with preference given to the thio group.
  • X 1 is preferably -(CH 2 ) m ⁇ (m represents 0, 1 or 2, preferably 0 or 1).
  • the optionally substituted hydrocarbon residue for Z 1 is exemplified by the same residues as those exemplifying the optionally substituted hydrocarbon residue for R mentioned above.
  • the heterocyclic group of the optionally substituted heterocyclic group for Z 1 is exemplified by (i) 5- to 7- membered heterocyclic groups containing 1 sulfur, nitrogen or oxygen atom; (ii) 5- or 6-membered heterocyclic groups containing 2 to 4 nitrogen atoms, and (iii) 5- or 6- membered heterocyclic groups containing 1 or 2 nitrogen atoms and 1 sulfur atom or 1 oxygen atom; these heterocyclic groups may be condensed with a 6-membered ring containing 2 or fewer nitrogen atoms, a benzene ring, or a 5-membered ring containing 1 sulfur atom.
  • heterocyclic groups examples include 2- pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4- pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 2-pyrrolyl, 3-pyrrolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyrazolyl, 4- pyrazolyl, isothiazolyl, isoxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, l,2,4-triazol-3-yl, l,3,4-triazol-2-yl, l,2,3-triazol-4-yl, tetrazol-5-yl, benzimidazol-2-yl, indol-3-yl,
  • the optionally substituted heterocyclic group for Zi is preferably an aromatic 5-membered heterocyclic groups containing 2 or 3 hetero atoms (e.g., oxygen atom, nitrogen atom, sulfur atom) , with greater preference given to 2- imidazolyl, l,2,4-triazol-3-yl.
  • hetero atoms e.g., oxygen atom, nitrogen atom, sulfur atom
  • the optionally substituted heterocyclic group for R is exemplified by the same groups as those exemplifying the optionally substituted heterocyclic group for Zi mentioned above.
  • the hydrocarbon residue and the heterocyclic group each represented by R or Z 1 mentioned above may have 1 to 3 substituents at any optionally substitutional positions on the ring thereof.
  • substituents include aliphatic chain hydrocarbon groups, alicyclic hydrocarbon groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, halogen atoms, nitro groups, optionally substituted amino groups, optionally substituted acyl groups, optionally substituted hydroxyl groups, optionally substituted thiol groups, and optionally esterified carboxyl groups.
  • Aliphatic chain hydrocarbon groups mentioned as substituents for the hydrocarbon residue and heterocyclic group each represented by R or Z 1 include linear or branched-chain aliphatic hydrocarbon groups such as alkyl groups (preferably C ⁇ - ⁇ o alkyl), alkenyl groups (preferably C2-10 alkenyl), and alkinyl groups (preferably C 2 - 10 alkinyl) .
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert- pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, hexyl, pentyl, octyl, nonyl and decyl.
  • alkenyl groups include vinyl, allyl, isopropenyl, 1-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-l-butenyl, 3- methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 4-hexenyl and 5-hexenyl.
  • alkinyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.
  • Alicyclic hydrocarbon groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 , include saturated or unsaturated
  • C 3 -. 8 alicyclic hydrocarbon groups such as C 3 -. 8 cycloalkyl groups, C 3 - 8 cycloalkenyl groups and C - 8 cycloalkadienyl groups.
  • C 3 - 8 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo
  • C 3 _ ⁇ cycloalkenyl groups include those having 5 to 7 carbon atoms, such as 2- cyclopenten-1-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl and
  • C-j- ⁇ cycloalkadienyl groups include those having 5 to 7 carbon atoms, such as 2,4- cyclopentadien-1-yl, 2,4-cyclohexadien-l-yl and 2,5- cyclohexadien-1-yl.
  • Aryl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 are monocyclic or condensed polycyclic aromatic hydrocarbon groups, preferably phenyl. naphthyl, anthryl, phenanthryl, acenaphthylenyl and others, with greater preference given to phenyl, 1-naphthyl, 2- naphthyl and others.
  • aromatic heterocyclic groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include aromatic monocyclic heterocyclic groups (e.g., furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl); and aromatic condensed heterocyclic groups (e.g., benzofurany
  • non-aromatic heterocyclic groups mentioned as substituents for the hydrocarbon residue and heterocyclic group include oxylanyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperizinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl and piperazinyl.
  • halogens mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include fluorine, chlorine, bromine and iodine, with preference given to fluorine and chlorine.
  • Examples of the optionally substituted amino groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include the amino group and substituted amino groups having 1 or 2 substituents selected from C ⁇ - ⁇ o alkyl groups, C 2 - 10 alkenyl groups, C 2 - 10 alkinyl groups, aromatic groups and so on (e.g., methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamino, N-methyl-N-phenylamino) .
  • Examples of the optionally substituted acyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include formyl and groups resulting from binding of an C ⁇ - 10 alkyl group, an C2- 1 0 alkenyl group, C 2 -10 alkinyl group or an aromatic group, and a carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2- cyclohexenecarbonyl, benzoyl, nicotinoyl).
  • Examples of the optionally substituted hydroxyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include hydroxyl group and substituted hydroxyl groups having an appropriate substituent, particularly a substituent for use as a hydroxyl group protecting group, such as alkoxy, alkenyloxy, aralkyloxy and acyloxy, as well as aryloxy.
  • Said alkoxy is preferably C ⁇ - 10 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy) .
  • alkoxy e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy
  • alkenyloxy is exemplified by C 2 - 1 0 alkenyloxy (e.g., allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2- cyclopentenylmethoxy and 2-cyclohexenylmethoxy) .
  • Said alkinyloxy is exemplified by C 2 - 1 0 alkinyloxy.
  • Said aralkyloxy is exemplified by phenyl-C ⁇ - 4 alkyloxys (e.g., benzyloxy, phenethyloxy) .
  • Said acyloxy is preferably an C 2 - 4 alkanoyloxy (e.g., acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy) .
  • Said aryloxy is exemplified by phenoxy and 4- chlorophenoxy.
  • Examples of the optionally substituted thiol groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 , include thiol group and substituted thiol groups having an appropriate substituent, particularly a substituent for use as a thiol group protecting group, such as alkylthio, alkenylthio, alkinylthio, aralkylthio and acylthio.
  • Said alkylthio is preferably C ⁇ - 10 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, nonylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio) .
  • alkylthio e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopenty
  • Said alkenylthio is preferably C 2 - 10 alkenylthio.
  • Said alkinylthio is preferably C 2 - 10 alkinylthio.
  • Said aralkylthio is exemplified by phenyl-C ⁇ - 4 alkylthios (e.g., benzylthio, phenethylthio) .
  • Said acylthio is preferably a C 2 - 4 alkanoylthio (e.g., acetylthio, propionylthio, n-butyrylthio, isobutyrylthio) .
  • Examples of the optionally esterified carboxyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z 1 include carboxyl group, groups resulting from binding of a carboxyl group and an C 1 - 6 alkyl group (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl.
  • tert-butoxycarbonyl pentyloxycarbonyl and hexyloxycarbonyl
  • groups resulting from binding of a carboxyl group and an C 3 -. 6 alkenyl group e.g., allyloxycarbonyl, crotyloxycarbonyl, 2-pentenyloxycarbonyl and 3-hexenyloxycarbonyl
  • groups resulting from binding of a carbonyl group and an aralkyl group e.g., benzyloxycarbonyl and phenethyloxycarbonyl
  • the substituent on the hydrocarbon residue and heterocyclic group may optionally have further one or more, preferably 1 to 3, substituents at any substitutional positions.
  • substituents include C ⁇ _ ⁇ o lower alkyl groups, C 2 - 10 lower alkenyl groups, C 2 - 10 lower alkinyl groups, C 3 - 7 cycloalkyl groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, aralkyl groups (e.g., aryl-C ⁇ - 6 alkyl), amino groups, N-mono-substituted amino groups, N,N-di-substituted amino groups, amidino groups, acyl groups, carbamoyl groups, N-mono-substituted carbamoyl groups (e.g., methylcarbamoyl, ethylcarbamoyl, phenylcarbamoyl)
  • R is -CH 2 -X 1 - Z 1
  • the optionally substituted amino group for Z* is represented by -N(R 1 )(R 2 ) (R 1 and R 2 , whether identical or not, represent a hydrogen atom, an optionally substituted hydrocarbon residue, or an optionally substituted heterocyclic group; or R 1 and R 2 may bind together to form a ring) .
  • the optionally substituted hydrocarbon residue or optionally substituted heterocyclic group for R 1 or R 2 is exemplified by the same optionally substituted hydrocarbon residues or optionally substituted heterocyclic group as those mentioned to exemplify the group for R above.
  • the hydrocarbon residue and heterocyclic group may have 1 to 3 substituents at any substitutional positions on the chain or the ring thereof.
  • substituents are exemplified by the same substituents as those for the hydrocarbon residue and heterocyclic group for R.
  • substituents on the hydrocarbon residue and heterocyclic group for R 1 or R 2 may have 1 or more, preferably 1 to 3, substituents at any substitutional positions. Examples of such substituents include C ⁇ - 10 lower alkyl groups, C 2 - 10 lower alkenyl groups, C 2 - 10 lower alkinyl groups, C 3 ..
  • R 1 and R 2 may bind together to form a ring; such -NfR 1 ) ⁇ 2 ) rings include 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, 1-piperidinyl, 1-piperazinyl, 4- morpholinyl, 4-thiomorpholinyl, homopiperazin-1-yl, 1,2,4- triazol-1-yl, 1,3,4-triazol-l-yl, pyrazol-1-yl, imidazol-1- yl, 1,2,3-triazol-l-yl, l,2,3-triazol-2-yl, tetrazol-1-yl, benzimidazol-1-yl, indol-1-yl and lH-indazol-1-yl.
  • the optionally oxidized sulfur atom, represented by X, is exemplified by thio group, sulfinyl group and sulfonyl group, with preference given to the thio group.
  • rings A and B may each have a substituent.
  • substituents include halogen atoms, nitro groups, optionally substituted C ⁇ _ ⁇ o alkyl, C 2 - 10 alkenyl, C 2 - 10 alkinyl groups, optionally substituted hydroxyl groups, optionally substituted thiol groups, optionally substituted amino groups, optionally substituted acyl groups (e.g., C ⁇ _ ⁇ o alkanoyl, C2-10 alkenoyl, C 2 - 1 0 alkinoyl groups etc.), optionally esterified carboxyl groups, and optionally substituted aromatic ring groups.
  • halogens mentioned as substituents for rings A and B include fluorine, chlorine, bromine and iodine, with preference given to fluorine and chlorine.
  • optionally substituted C ⁇ - 10 alkyl groups mentioned as substituents for rings A and B may be linear C ⁇ - 10 alkyl, branched C 3 - 10 alkyl or C 3 - 1 0 cyclic alkyl, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • substituents for rings A and B examples include the hydroxyl group and substituted hydroxyl groups having an appropriate substituent, particularly a substituent for use as a hydroxyl group-protecting group, such as alkoxy, alkenyloxy, aralkyloxy and acyloxy, as well as aryloxy.
  • Said alkoxy is preferably a C ⁇ - ⁇ o alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy) .
  • a C ⁇ - ⁇ o alkoxy e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy
  • Said alkenyloxy is exemplified by C 2 - 10 alkenyloxys (e.g., allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2- cyclopentenyl ethoxy and 2-cyclohexenylmethoxy) .
  • Said alkinyloxy is preferably a C 2 - 10 alkinyloxy.
  • Said aralkyloxy is exemplified by phenyl-C ⁇ _ 4 alkoxy (e.g., benzyloxy, phenethyloxy) .
  • Said acyloxy is preferably a C 2 - 4 alkanoyloxy (e.g., acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy) .
  • Said aryloxy is exemplified by phenoxy, 4- chlorophenoxy and so on.
  • Examples of the optionally substituted thiol groups mentioned as substituents for rings A and B include thiol group and substituted thiol groups having an appropriate substituent, particularly a substituent for use as a thiol group-protecting group, such as alkylthio, alkenylthio, alkinylthio, aralkylthio, acylthio and arylthio.
  • Said alkylthio is preferably a C ⁇ - 10 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, nonylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio) .
  • alkylthio e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopen
  • Said alkenylthio is preferably a C 2 - 10 alkenylthio.
  • Said alkinylthio is preferably a C 2 - 10 alkinylthio.
  • Said aralkylthio is exemplified by phenyl-C_,_ 4 alkylthios (e.g., benzylthio, phenethylthio) .
  • Said acylthio is preferably a C 2 - 4 alkanoylthio (e.g., acetylthio, propionylthio, n-butyrylthio, isobutyrylthio) .
  • Said arylthio is exemplified by phenylthio, 4- chlorophenyl, and so on.
  • Examples of the optionally substituted amino groups mentioned as substituents for rings A and B include amino group and substituted amino groups having 1 or 2 substituted selected from C ⁇ - 10 alkyl groups, C 2 - 10 alkenyl groups, C 2 - 10 alkinyl groups and aromatic groups and so on (e.g., methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamino, N-methyl-N-phenylamino) .
  • 1 or 2 substituted selected from C ⁇ - 10 alkyl groups, C 2 - 10 alkenyl groups, C 2 - 10 alkinyl groups and aromatic groups and so on e.g., methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamin
  • Examples of the optionally substituted acyl groups mentioned as substituents for rings A and B, include formyl and the groups resulting from binding of a C ⁇ _ ⁇ o alkyl group, C 2 - 10 alkenyl group, C 2 - 10 alkinyl group or aromatic group and a carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2-cyclohexenecarbonyl, benzoyl, nicotinoyl).
  • a carbonyl group e.g., acetyl, propionyl, butyryl, isobutyryl, va
  • Examples of the optionally esterified carboxyl groups mentioned as substituents for rings A and B include carboxyl group, groups resulting from binding of a carboxyl group and a Ci- ⁇ alkyl group (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl) , groups resulting from binding of a carboxyl group and a C 3 - 6 alkenyl group (e.g., allyloxycarbonyl, crotyloxycarbonyl, 2-pentenyloxycarbonyl and 3-hexenyloxycarbonyl) , and groups resulting from binding of a carbonyl group and an aralkyloxy group, (e.g., benzyloxycarbonyl, phenethyl
  • Examples of the optionally substituted aromatic ring groups mentioned as substituents for rings A and B include C ⁇ - 1 aromatic hydrocarbon residues (e.g., phenyl, naphthyl, anthryl etc.), and heterocyclic aromatic residues (e.g., pyridyl, furyl, thienyl, imidazolyl and thiazolyl).
  • C ⁇ - 1 aromatic hydrocarbon residues e.g., phenyl, naphthyl, anthryl etc.
  • heterocyclic aromatic residues e.g., pyridyl, furyl, thienyl, imidazolyl and thiazolyl.
  • substituents for rings A and B may each be present at any substitutional position of the ring thereof; 1 to 4 identical or different substituents may be present.
  • substituents on ring A or B are mutually adjoining, they may bind together to form a ring represented by -(CH 2 ) t ⁇ or -0-(CH 2 ) ⁇ 0- (t is an integer from 3 to 5; 1 is an integer from 1 to 3); such rings include 5- to 7-membered rings formed in cooperation with carbon atoms of the benzene ring.
  • ring A is substituted for by at least 1 alkoxy group, preferably C ⁇ _ 3 alkoxy group, more preferably by at least 1 methoxy group. Still more preferably, ring A is substituted for by 2 identical or different alkoxy groups, preferably C 1 - 3 alkoxy group, more preferably by methoxy groups. Most preferably, ring A is substituted for by 2 methoxy groups respectively at the 6- and 7-positions of the quinoline ring or quinazoline ring.
  • ring B is substituted for by at least 1 alkoxy group, preferably C 1 -. 3 alkoxy group, more preferably at least 1 methoxy or isopropoxy group.
  • ring B is substituted for by 2 identical or different alkoxy groups, preferably C 1 -. 3 alkoxy group. Most preferably, ring B is substituted for by a methoxy or isopropoxy group at the 3-position and by a methoxy group at the 4-position.
  • the optionally esterified carboxyl group for G is exemplified by carboxyl group, alkoxycarbonyl groups and aralkyloxycarbonyl group.
  • the alkyl group in said alkoxycarbonyl groups is exemplified by Ci- ⁇ alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl).
  • the aralkyl group in said aralkyloxycarbonyl groups is an alkyl group having an aryl group as a substituent (aryl- alkyl group) .
  • Said aryl group is exemplified by phenyl and naphthyl, each of which may have the same substituents as those for ring A above.
  • Said alkyl group is preferably a lower C ⁇ - 6 alkyl group.
  • Preferable aralkyl groups include benzyl, phenethyl, 3-phenylpropyl, (l-naphthyl)methyl and (2-naphthyl)methyl, with preference given to benzyl, phenetyl and others.
  • G is an amidated carboxyl group, it is represented by -CONfR 1 ) ⁇ 2 ) (R 1 and R 2 have the same definitions as those given above).
  • the acyl group for G in the above formula (I) is represented, for example, by the formula: -CO-R3 in which R3 is an alkyl group or an aryl group.
  • R3 is an alkyl group or an aryl group.
  • the alkyl group for R3 include C 1 - 5 alkyl groups (e.g., methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, etc.).
  • Preferred examples of the alkyl group for R3 include methyl, butyl, isobutyl, pentyl, etc..
  • Examples of the aryl gorup for R 3 includes a monocyclic or condensed polycyclic aromatic hydrocarbon group having 6 to 14 carbon atoms.
  • Preferred examples of the aryl group for R3 include phenyl, naphthyl, anthryl, phenanthryl, etc.. In particular, phenyl, 1-naphthyl, 2-naphthyl, etc., are more preferred.
  • G is hydroxyalkyl
  • the alkyl group of the hydroxyalkyl group for G includes the above alkyl groups represented by Ri or R2.
  • the hydroxyalkyl group is represented by the formula: -CH 2 OH or -CH(OH)-R3 in which R3 is an defined above.
  • R3 in this formula is preferably methyl, ethyl, etc..
  • the protected hydroxy moiety may be the above substituted hydroxyl group as the substituent of the hydrocarbon group or heterocyclic group represented by R* or R2.
  • the protected hydroxyalkyl group is represented by the formula: -C ⁇ OCOR-i or -CH(OCOR-»)-R3 in which R3 is as defined above and R4 is an alkyl group, aralkyl group or aryl group each of which may optionally be substituted.
  • the alkyl group for R4 includes, for example, C ⁇ - 6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, etc..
  • the aralkyl group for R4 means, for example, a C ⁇ - 14 aryl-C ⁇ _ 4 alkyl group.
  • Specific examples of the alkyl group in the aralkyl group include the above alkyl groups represented by R4.
  • specific examples of the aryl group in the aralkyl group include phenyl, naphthyl, etc.
  • aralkyl group examples include benzyl, phenethyl, 3-phenylpropyl, (1- naphthy1)methyl, (2-naphthyl)methyl, etc.
  • the aryl group for R4 includes, for example, aryl group having 6 to 14 carbon atoms such as phenyl, naphthyl, etc..
  • R 3 represents a hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted heterocyclic group; the other symbols have the same definitions as those given above.
  • Y is preferably C-G, with greater preference given to a C ⁇ - 6 alkoxycarbonyl group for G, and greatest preference given to an ethoxycarbonyl group for G.
  • n in the above formula (I) is preferably 0.
  • k in the above formula (I) is preferably 0.
  • Y is C-G (G is ethoxycarbonyl)
  • R is -CH 2 -Z 1
  • Z 1 is 1,2,4-triazol-l-yl
  • the substituents for ring A are methoxy groups each present at the 6- and 7-position of the quinoline ring
  • each substituent for ring B is methoxy or isopropoxy group present at the 3-position and methoxy groups present at the 4-position thereof
  • n is 0, and k is 0.
  • the above compound (I) can be produced according to the production methods described in detail, for instance, in Japanese Patent Unexamined Publication (Kokai tokkyo koho) Nos. 306052/1994(EP-A-0567107), 118266/1995(EP-A- 0608870), 69890/1995(EP-A-0634169), 53419/1996(EP-A- 0686630) and W095/24394.
  • the salt of compound (I) for the present invention is preferably a pharmaceutically acceptable salt, exemplified by salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids and salts with basic or acidic amino acids.
  • Preferable salts with inorganic base include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salt and ammonium salt.
  • Preferable salts with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and N,N'-dibenzylethylenediamine.
  • Preferable salts with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid.
  • Preferable salts with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
  • Preferable salts with basic amino acid include salts with arginine, lysine and ornithine.
  • Preferable salts with acidic amino acid include salts with aspartic acid and glutamic acid. Amont these salts, sodium or patassium salts are most preferable.
  • the compound (I) or a salt thereof of the present invention may be a hydrate.
  • the pharmaceutical agent combined with a little slowly acting quinoline or quinazoline compound for the prophylaxis or therapeuticy of arthritis is what is called a rapidly acting anti- inflammatory analgesic agent which clinically suppresses inflammation and accompanying pain in 30 minutes or in 2 to 3 days, at latest within 1 week, after administration.
  • rapidly acting anti-inflammatory analgesics can be classified in various manners according to chemical structure, action etc., but those advantageous for use in the present invention include ® cyclooxygenase inhibitors, (D central analgesics, D steroids, and (D anti- inflammatory enzyme agents.
  • Cyclooxygenase inhibitors are compounds that suppress cyclooxygenase 1 and/or cyclooxygenase 2; preferable examples include the following compounds and salts thereof.
  • Salicylic acid derivatives possessing anti- inflammatory analgesic activity such as aspirin; pyrazolone derivatives possessing anti-inflammatory analgesic activity, such as antipyrine; phenylbutazone, oxybutazone, sulfinpyrazone, acemetacin, alclofenac, alminoprofen, anfenac, ampiroxicam, butybufen, calprofen, dichlofenac, diflunisal, droxicam, etodolac, fenbufen, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, indomethacin, indomethacin farnesil ester, ketoprofen, ketorolac, loxoprofen, mefenamic acid, meclofenamate, meloxicam, nabumetone, naproxen, oxaprozin, pirazolac, piroxi
  • W095/15315 W095/ 15316, W095/15317 and W095/15318 and salts thereof. More specifically, preferable compounds include the compounds described in claim 16 for W095/15315 above [e.g., l-[(4- alkylsulfonyl)phenyl]-3-substitutional-5-substitutional-lH- pyrazole derivatives], i.e.,
  • R5 is aryl which is substituted with substituent(s) selected from the group consisting of C ⁇ - 6 alkylthio, cyclo C ⁇ _6 alkyl, hydroxy, hydroxy C ⁇ - 6 alkyl, cyano, Ci- ⁇ alkylenedioxy, acyl, acyloxy, aryloxy and Ci- ⁇ alkoxy optionally substituted with acyl or C ⁇ - 6 alkoxy;
  • R6 is halogen, halo C ⁇ - 6 alkyl, cyano or acyl, and
  • R7 is aryl substituted with nitro, hydroxy, C ⁇ -_. alkoxy, Ci 6 alkylthio, C ⁇ -e alkylsulfinyl or Ci- ⁇ alkylsulfonyl; provided that when R? is aryl substituted with nitro, hydroxy or lower alkoxy, then R5 is aryl substituted with C ⁇ - 6 alkylthio, C ⁇ - 6 alkylsulfinyl or C ⁇ _6 alkylsulfonyl.
  • 5 is phenyl which is substituted with substituent(s) selected from the group consisting of hydroxy, hydroxy C ⁇ _g alkyl, cyano, C_.- 6 alkylenedioxy, acyl, acyloxy, aryloxy and C ⁇ _ 6 alkoxy optionally substituted with acyl or C ⁇ - 6 alkoxy, and preferably phenyl substituted with cyano, C ⁇ - 6 alkanoyl or C ⁇ _ 6 alkoxy, and more preferably phenyl substituted with cyano or methoxy.
  • substituent(s) selected from the group consisting of hydroxy, hydroxy C ⁇ _g alkyl, cyano, C_.- 6 alkylenedioxy, acyl, acyloxy, aryloxy and C ⁇ _ 6 alkoxy optionally substituted with acyl or C ⁇ - 6 alkoxy, and preferably phenyl substituted with cyano, C ⁇ - 6 alkanoyl or C ⁇ _ 6 alkoxy,
  • R 7 is phenyl substituted with C ⁇ - 6 alkylthio, C ⁇ - 6 alkylsulfinyl or C ⁇ - 6 alkylsulfonyl, preferably phenyl substituted with methylthio, methylsulfinyl or methylsulfonyl.
  • R6 is halogen or halo Ci- ⁇ alkyl, preferably bromine, difluoromethyl or trifluoromethyl.
  • Preferable examples of compounds represented by the formula (IV) is 3-(difluoromethyl)-l-(4-methoxyphenyl)-5- [4-(methylsulfonyl)phenyl]pyrazole, or 3-(difluoromethyl)- 1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole.
  • Central analgesics generically refer to narcotic or non-narcotic analgesics; preferable examples include the following compounds and salts thereof.
  • Steroids refer to all corticosteroids possessing anti- inflammatory activity; preferable examples include the following compounds and salts thereof.
  • Betamethasone, dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, triamcinolone and paramethasone are examples of dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, triamcinolone and paramethasone.
  • Anti-inflammatory enzyme agents generically refer to proteins possessing acute inflammation-suppressing activity and/or analgesic activity; preferable examples include the following.
  • Bromelins Bromelins, lysozyme, promelase, pronase, serrapeptase, streptokinase, chymotrypsin and amylase.
  • anti-inflammatory analgesics may be in the form of pharmaceutically acceptable salts, as with compound (I).
  • the pharmaceutical composition of the present invention comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic, can be administered orally or non-orally in the form of granules, powders, tablets, capsules, syrups, suppositories, injectable preparations, emulsions, elixirs, suspensions, solutions etc., as prepared separately or simultaneously by mixing with physiologically acceptable carriers, excipients, binders, diluents etc.
  • the resulting separate preparations can be administered in the form of a mixture with diluents etc. prepared freshly at the time of use; however, separate preparations may be administered to the same subject separately, simultaneously or at intervals.
  • the pharmaceutical composition of the present invention can be prepared as various dosage forms in accordance with ordinary methods.
  • non-oral encompasses subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection and drip infusion.
  • Preparations for injection e.g., aqueous or oily suspensions for aseptic injection, can be prepared by methods known to those skilled in the art, using an appropriate dispersing agent or a wetting agent and a suspending agent.
  • the preparation for aseptic injection may be a solution or suspension permitting aseptic injection in a diluent or solution that is non-toxic and administrable non-orally, such as an aqueous solution.
  • Useful vehicles or solvents include water. Ringer's solution and isotonic saline.
  • Aseptic nonvolatile oils can also be used as solvents or suspending media.
  • any nonvolatile oils or fatty acids can be used, including natural, synthetic or semi-synthetic fatty oils and fatty acids, and natural, synthetic or semi- synthetic mono-, di- or tri-glycerides.
  • Suppositories for rectal administration can be produced by mixing the drug and an appropriate non- irritative excipient that is solid at normal temperature but liquid at gut temperature and melts to release the drug in the rectum, such as cocoa butter or polyethylene glycol.
  • Solid dosage forms for oral administration include powders, granules, tablets, pills and capsules, as mentioned above.
  • the active ingredient compound can be mixed with at least 1 additive selected from the group consisting of sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starches, agar, alginates, chitins, chitosans, pectins, gum tragacanth, gum arabic, gelatins, collagens, casein, albumin, and synthetic or semi-synthesis polymers and glycerides.
  • these dosage forms can contain additional additives, including inert diluents, lubricants such as magnesium stearate, preservatives such as parabens and sorbic acid, antioxidants such as ascorbic acid, a- tocopherol and cysteine, disintegrating agents, binders, thickening agents, buffers, sweetening agents, flavoring agents and perfumes. Tablets and pills can also be produced with enteric coating.
  • Liquid preparations for oral administration include pharmaceutically acceptable emulsions, syrups, elixirs, suspensions and solutions, and may contain inert diluents in common use in the relevant art, such as water.
  • a daily dose of each pharmaceutical agent can be chosen appropriately, according to patient age, body weight, symptoms, administration time, dosage form, administration method, combination of each pharmaceutical agent etc., it can be chosen over the range of 5-1000 mg preferably 10-200 mg, per adult person, the likely clinical dose range for oral administration, and over the range of 0.1-100 mg, preferably 1-100 mg per adult person for non- oral adminstration in the case of quinoline or quinazoline compound for prophylaxis or therapy of arthritis; and can be increased or decreased as appropriate on the basis of the likely clinical dose range for oral administration in the case of rapidly acting anti-inflammatory analgesics such as ⁇ cyclooxygenase inhibitors, ⁇ central analgesics, ⁇ steroids, and (D anti-inflammatory enzyme agents.
  • analgesics such as ⁇ cyclooxygenase inhibitors, ⁇ central analgesics, ⁇ steroids, and (D anti-inflammatory enzyme agents.
  • the dose can be chosen as appropriate according to the situation on the basis of the likely clinical dose range when individual drugs are used singly.
  • the dose for oral administration can be chosen over the range of 1- 5000 mg, preferably 25-4500 mg per adult person, for example, 1000-4500 mg for aspirin, 50-150 mg for indomethachin, 25-75 mg for diclofenac, 60-180 mg for loxoprofen, and the dose for non-oral administration can be chosen over the range of 0.2-200 mg, preferably 1-100 mg per adult person.
  • the dose for oral administration can be chosen over the range of 1-1000 mg, preferably 5-300 mg per adult person, for example, 10-60 mg for morphine, and the dose for non-oral administration can be chosen over the range of 0.1-300 mg, preferably 0.5-100 mg per adult person for example, 5-60 mg, for morphine.
  • the dose for oral administration can be chosen over the range of 0.1-400 mg, preferably 0.5-100 mg per adult person, for example, 5-100 mg, for prednisolone, and 0.5-10 mg for dexamethasone
  • the dose for non-oral administration can be chosen over the range of 0.1-100 mg, preferably 0.5-25 mg per adult person for example, 5-25 mg for prednisolone, 0.5-2.5 mg for dexamethasone.
  • the dose for oral administration can be chosen over the range of 5-40 mg, per adult person.
  • Appropriate administration frequency is 1 to 3 times daily.
  • a pharmaceutical composition of the present invention comprising a combination of the agents mentioned above has low toxity.
  • the combined pharmaceutical provided by the present invention exhibits excellent rapidly acting and sustained anti-inflammatory analgesic action against arthritis, especially rheumatoid arthritis, with very low prevalence of side effects even in chronic administration, provided that drug combination, administration method, dose etc. are appropriately chosen according to symptoms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical exhibiting rapidly acting and sustained anti-inflammatory analgesic action against chronic arthritis, with low prevalence of side effects. A pharmaceutical comprising a combination of a quinoline/quinazoline-series prophylactic/therapeutic agent for arthritis and rapidly acting anti-inflammatory analgesics including (1) a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid, or (4) an anti-inflammatory enzyme agent. Exhibits excellent effect against arthritis from initial stage of administration, ensuring stable anti-inflammatory analgesic action with low prevalence of side effects even in chronic administration, provided that drug combination, administration method and dose are appropriately chosen according to symptoms.

Description

DESCRIPTION THERAPEUTIC COMPOSITION FOR ARTHRITIS
Technical Field The present invention relates to a pharmaceutical composition that serves well as a therapeutic agent for arthritis, especially as an anti-rheumatic agent.
Background Art Arthritis, an inflammatory disease of the joints, occurs in various forms, such as rheumatoid arthritis and related diseases with joint inflammation.
Rheumatoid arthritis, also called chronic rheumatism, is a chronic multiple arthritis characterized by inflammatory changes in the synovial membrane of the articular capsule inner layer. Arthritic diseases such as rheumatoid arthritis are progressive, and cause joint disorders such as deformation and acampsia, often resulting in severe physical disorder due to a lack of effective treatment and subsequent deterioration.
Traditionally, these forms of arthritis have been chemotherapeutically treated with various agents, including steroids such as cortisone and other adrenocortical hormones, non-steroidal anti-inflammatory agents such as aspirin, piroxicam and indomethacin, gold agents such as aurothiomalate, antirheumatic agents such as chloroquine preparations and D-penicillamine, anti-gout agents such as colchicine, and immunosuppressors such as cyclophosphamide, azathioprine, methotrexate and levamisole. However, these drugs have drawbacks such as severe side effects hampering the drug's long-term use, a lack of anti-inflammatory effect and a failure to be effective against already- occurring arthritis.
In recent years, new prophylactic/therapeutic agents for arthritis having a quinoline/quinazoline skeleton have been increasingly appreciated for their low toxicity and excellent prophylactic/therapeutic effect against arthritis. However, several weeks to months are required to obtain the desired effect from the use of a quinoline/ quinazoline-series prophylactic/therapeutic agent for arthritis, because the radical cause of chronic arthritis is prevented and treated through improvement of immunological anomalies and action on bone and cartilage. There has therefore been a need for a solution to these problems and for the development of a therapeutic agent for arthritis showing symptomatic effect against acute inflammatory symptoms and pain.
Disclosure of Invention
The present inventors found that excellent anti- inflammatory analgesic effect against chronic arthritis can be obtained from initial treatment, and sustained safely for an extended period of time, by administering a pharmaceutical comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent possessing acute inflammation-suppressing and analgesic activities, providing clinical effect in 30 minutes, in 2 to 3 days or at latest within 1 week, such as φ a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid, or ® an anti-inflammatory enzyme agent. The inventors conducted further investigation based on this finding, and developed the present invention.
Accordingly, the present invention relates to:
(1) A pharmaceutical composition comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
(2) The pharmaceutical composition of the above item (1), wherein said rapidly acting anti-inflammatory analgesic agent is a cyclooxygenase inhibitor. (3) The pharmaceutical composition of the above item (1), wherein said rapidly acting anti-inflammatory analgesic agent is a central analgesic.
(4) The pharmaceutical composition of the above item (1), wherein said rapidly acting anti-inflammatory analgesic agent is a steroid.
(5) The pharmaceutical composition of the above item (1), wherein said rapidly acting anti-inflammatory analgesic agent is an anti-inflammatory enzyme agent. (6) The pharmaceutical composition of the above item
(1), wherein said quinoline or quinazoline compound for the prophylaxis or therapy of arthritis contains as an active ingredient a compound represented by the formula (I):
Figure imgf000005_0001
wherein Y represents a nitrogen atom or C-G (G represents a carboxyl group which may be esterified or amidated, an acyl, or a hydroxyalkyl group); R represents an optionally substituted hydrocarbon residue, or an optionally substituted heterocyclic group; X represents an oxygen atom or an optionally oxidized sulfur atom; n represents 0 or 1; k represents 0 or 1; G and R may bind together to form a ring; rings A and B may each have a substituent; or a pharmaceutically acceptable salt thereof.
(7) The pharmaceutical composition of the above item (6), wherein n represents 0 and the optionally substituted hydrocarbon residue for R is a group represented by the formula: -CH2-X1-Z1 , wherein X1 represents an oxygen atom, an optionally oxidized sulfur atom or -(CH2)m- (m represents an integer from 0 to 5); Z1 represents an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an optionally substituted amino group. (8) The pharmaceutical composition of the above item (7), wherein X1 is -(CH2)m~ (πι is 0 or 1).
(9) The pharmaceutical composition of the above item (7), wherein the optionally substituted heterocyclic group for Z1 is an aromatic 5-membered heterocyclic group containing 2 or 3 hetero atoms.
(10) The pharmaceutical composition of the above item (6), wherein Y is C-G.
(11) The pharmaceutical composition of the above item (10), wherein G is a Cι-β alkoxycarbonyl group. (12) The pharmaceutical composition of the above item
(10), wherein G is an ethoxycarbonyl group.
(13) The pharmaceutical composition of the above item
(6), wherein ring A is substituted for by at least one alkoxy group. (14) The pharmaceutical composition of the above item
(6), wherein ring A is substituted for by two methoxy groups.
(15) The pharmaceutical composition of the above item (14), wherein ring A is substituted for by two methoxy groups respectively at the 6- and 7-positions of the quinoline ring or quinazoline ring.
(16) The pharmaceutical composition of the above item (6), wherein ring B is substituted for by at least one alkoxy group. (17) The pharmaceutical composition of the above item
(6), wherein ring B is substituted for by two identical or different alkoxy groups.
(18) The pharmaceutical composition of the above item
(6) , wherein k is 0. (19) The pharmaceutical composition of the above item
(6), wherein the compound represented by the formula (I) is 6,7-dimethoxy-9-phenylfuro[3,4-b]quinolin-l(3H)-one; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (1- methylimidazol-2-yl)thiomethyl]quinoline-3-carboxylate;
4-(3,4-dimethoxyphenyl)-2-(2-hydroxyethylthiomethyl)- 6,7-dimethoxyquinazoline;
4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (4-methyl- 1,2,4-triazol-3-yl)thiomethyl]quinazoline; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[2-(1- methylimidazol-2-yl)ethyl]quinoline-3-carboxylate; methyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3- methoxycarbonylquinoline-2-acetate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3-isopropoxy-4-methoxyphenyl)-6,7-dimethoxy- 2-(l,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxy-2- (l,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 7-hydroxy-6-methoxy-4-(3,4-dimethoxyphenyl)-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-l-ylmethyl)quinoline-3-carboxylate 1-oxide; or ethyl 2-(N, -diethylaminomethyl)-4-(3,4- dimethoxyphenyl)-6,7-dimethoxyquinoline-3-carboxylate.
(20) A therapeutic agent for arthritis comprising a combination of a qunoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
(21) A method of treating an arthritis and/or an inflammation in mammals which comprises administering to the mammals a therapeutically effective amount of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
(22) The method according to the above item (21), wherein the quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and the rapidly acting anti-inflammatory analgesic agent are administered simultaneously.
(23) The method according to the above item (21), wherein the quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and the rapidly acting anti-inflammatory analgesic agent are administered sequentially.
(24) Use of a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent to manufacture a preparation for treating an arthritis and/or an infllamation in mammals.
Best Mode for Carrying Out the Invention Quinoline or quinazoline compound for the prophylaxis or therapy of arthritis useful for the present invention generically refer to the class of prophylactic/therapeutic agents for arthritis comprising compounds having a quinoline or quinazoline skeleton as an active ingredient. These compounds and their production methods are described in detail, for instance, in Japanese Patent Unexamined Publication (Kokai tokkyo koho) Nos. 306052/1994(EP-A- 0567107), 118266/1995(EP-A-0608870), 69890/1995(EP-A- 0634169), 53419/1996(EP-A-0686630) and W095/24394. Those compounds are practically represented by the above formula (I), all possess prophylactic/therapeutic activity against arthritis and are advantageously used for the present invention
In the above formula (I), the optionally substituted hydrocarbon residue for R is exemplified by aliphatic hydrocarbon residues, alicyclic hydrocarbon residues, alicyclic-aliphatic hydrocarbon residues, aromatic carbon ring-aliphatic hydrocarbon residues and aromatic hydrocarbon residues. Such aliphatic hydrocarbon residues include saturated aliphatic hydrocarbon residues having 1 to 8 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert- pentyl, hexyl, isohexyl, heptyl, octyl); and unsaturated aliphatic hydrocarbon residues having 2 to 8 carbon atoms (e.g., vinyl (ethenyl), 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l-propenyl, 1-pentenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1- hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1-heptenyl, 1-octenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4- pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexadynyl, 5-hexynyl, 1-heptynyl, 1-octynyl).
Such alicyclic hydrocarbon residues include saturated alicyclic hydrocarbon residues having 3 to 7 carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl) ; and unsaturated alicyclic hydrocarbon residues having 5 to 7 carbon atoms (e.g., 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2- cycloheptenyl, 3-cycloheptenyl, 2,4-cycloheptadienyl) .
Such alicyclic-aliphatic hydrocarbon residues include those comprising a combination of C4-9 one of the above- mentioned alicyclic hydrocarbon residues and one of the above-mentioned aliphatic hydrocarbon residues (e.g., cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3- cyclopentenylmethyl, cyclohexylmethyl, 2- cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, cycloheptylethyl) . Such aromatic carbon ring-aliphatic hydrocarbon residues include phenylalkyls having 7 to 9 carbon atoms (e.g., benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2- phenylpropyl, 1-phenylpropyl); and naphthylalkyls having 11 to 13 carbon atoms (e.g., α-naphthylmethyl, σ-naphthylethyl, ?-naphthylmethyl and /?-naphthylethyl) . Such aromatic hydrocarbon residues include phenyl and naphthyl (e.g., α-naphthyl, /?-naphthyl) .
The optionally substituted hydrocarbon residue for R is preferably a group represented by the formula: -CH -X1-Z1 wherein X1 represents an oxygen atom, an optionally oxidized sulfur atom, or -(CH2)m~ (m represents an integer from 0 to 5); Z1 represents an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group, or an optionally substituted amino group.
The optionally oxidized sulfur atom for X1, is exemplified by the thio group, sulfinyl group and sulfonyl group, with preference given to the thio group.
X1 is preferably -(CH2)m~ (m represents 0, 1 or 2, preferably 0 or 1).
The optionally substituted hydrocarbon residue for Z1 is exemplified by the same residues as those exemplifying the optionally substituted hydrocarbon residue for R mentioned above. The heterocyclic group of the optionally substituted heterocyclic group for Z1 is exemplified by (i) 5- to 7- membered heterocyclic groups containing 1 sulfur, nitrogen or oxygen atom; (ii) 5- or 6-membered heterocyclic groups containing 2 to 4 nitrogen atoms, and (iii) 5- or 6- membered heterocyclic groups containing 1 or 2 nitrogen atoms and 1 sulfur atom or 1 oxygen atom; these heterocyclic groups may be condensed with a 6-membered ring containing 2 or fewer nitrogen atoms, a benzene ring, or a 5-membered ring containing 1 sulfur atom. Examples of such heterocyclic groups include 2- pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4- pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 2-pyrrolyl, 3-pyrrolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyrazolyl, 4- pyrazolyl, isothiazolyl, isoxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, l,2,4-triazol-3-yl, l,3,4-triazol-2-yl, l,2,3-triazol-4-yl, tetrazol-5-yl, benzimidazol-2-yl, indol-3-yl, benzpyrazol- 3-yl, lH-pyrrolo[2,3-b]pyrazin-2-yl, lH-pyrrolo[2,3-b] pyridin-6-yl, lH-imidazo[4,5-b]pyridin-2-yl, lH-imidazo [4,5-c]pyridin-2-yl and lH-imidazo[4,5-b]pyrazin-2-yl.
The optionally substituted heterocyclic group for Zi is preferably an aromatic 5-membered heterocyclic groups containing 2 or 3 hetero atoms (e.g., oxygen atom, nitrogen atom, sulfur atom) , with greater preference given to 2- imidazolyl, l,2,4-triazol-3-yl.
In the above formula (I), the optionally substituted heterocyclic group for R is exemplified by the same groups as those exemplifying the optionally substituted heterocyclic group for Zi mentioned above. In the above formula (I), the hydrocarbon residue and the heterocyclic group each represented by R or Z1 mentioned above may have 1 to 3 substituents at any optionally substitutional positions on the ring thereof. Such substituents include aliphatic chain hydrocarbon groups, alicyclic hydrocarbon groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, halogen atoms, nitro groups, optionally substituted amino groups, optionally substituted acyl groups, optionally substituted hydroxyl groups, optionally substituted thiol groups, and optionally esterified carboxyl groups.
Aliphatic chain hydrocarbon groups mentioned as substituents for the hydrocarbon residue and heterocyclic group each represented by R or Z1 include linear or branched-chain aliphatic hydrocarbon groups such as alkyl groups (preferably Cι-ιo alkyl), alkenyl groups (preferably C2-10 alkenyl), and alkinyl groups (preferably C2-10 alkinyl) .
Preferable examples of the alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert- pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, hexyl, pentyl, octyl, nonyl and decyl.
Preferable examples of the alkenyl groups include vinyl, allyl, isopropenyl, 1-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-l-butenyl, 3- methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 4-hexenyl and 5-hexenyl.
Preferable examples of the alkinyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.
Alicyclic hydrocarbon groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include saturated or unsaturated
C3-.8 alicyclic hydrocarbon groups such as C3-.8 cycloalkyl groups, C3-8 cycloalkenyl groups and C -8 cycloalkadienyl groups.
Preferable examples of the C3-8 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo
[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.l.nonyl, bicyclo[4.2.1]nonyl and bicyclo[4.3.1]decyl. Preferable examples of the C3_β cycloalkenyl groups include those having 5 to 7 carbon atoms, such as 2- cyclopenten-1-yl, 3-cyclopenten-l-yl, 2-cyclohexen-l-yl and
3-cyclohexen-l-yl.
Preferable examples of the C-j-β cycloalkadienyl groups include those having 5 to 7 carbon atoms, such as 2,4- cyclopentadien-1-yl, 2,4-cyclohexadien-l-yl and 2,5- cyclohexadien-1-yl.
Aryl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, are monocyclic or condensed polycyclic aromatic hydrocarbon groups, preferably phenyl. naphthyl, anthryl, phenanthryl, acenaphthylenyl and others, with greater preference given to phenyl, 1-naphthyl, 2- naphthyl and others.
Preferable examples of aromatic heterocyclic groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include aromatic monocyclic heterocyclic groups (e.g., furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl); and aromatic condensed heterocyclic groups (e.g., benzofuranyl, isobenzofuranyl, benzo[b]thienyl, indolyl, isoindolyl, 1H- indazolyl, benzimidazolyl, benzoxazolyl, 1,2- benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 1H- benzotriazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthylizinyl, purinyl, pteridinyl, carbazolyl, α-carbolinyl, /?- carbolinyl, y-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenanthridinyl, phenanthrolinyl, indolizinyl, pyrrolo[l,2- bjpyridazinyl, pyrazolo[l,5-a]pyridyl, imidazo[l,2-a] pyridyl, imidazo[l,5-a]pyridyl, imidazo[l,2-b]pyridazinyl, imidazo[l,2-a]pyrimidinyl, 1,2,4-triazolo[4,3-a]pyridyl, l,2,4-triazolo[4,3-b]pyridazinyl) .
Preferable examples of the non-aromatic heterocyclic groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include oxylanyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperizinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl and piperazinyl. Examples of halogens mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include fluorine, chlorine, bromine and iodine, with preference given to fluorine and chlorine.
Examples of the optionally substituted amino groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include the amino group and substituted amino groups having 1 or 2 substituents selected from Cι-ιo alkyl groups, C2-10 alkenyl groups, C2-10 alkinyl groups, aromatic groups and so on (e.g., methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamino, N-methyl-N-phenylamino) .
Examples of the optionally substituted acyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include formyl and groups resulting from binding of an Cι-10 alkyl group, an C2-10 alkenyl group, C2-10 alkinyl group or an aromatic group, and a carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2- cyclohexenecarbonyl, benzoyl, nicotinoyl).
Examples of the optionally substituted hydroxyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include hydroxyl group and substituted hydroxyl groups having an appropriate substituent, particularly a substituent for use as a hydroxyl group protecting group, such as alkoxy, alkenyloxy, aralkyloxy and acyloxy, as well as aryloxy. Said alkoxy is preferably Cι-10 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy) . Said alkenyloxy is exemplified by C2-10 alkenyloxy (e.g., allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2- cyclopentenylmethoxy and 2-cyclohexenylmethoxy) .
Said alkinyloxy is exemplified by C2-10 alkinyloxy. Said aralkyloxy is exemplified by phenyl-Cι-4 alkyloxys (e.g., benzyloxy, phenethyloxy) .
Said acyloxy is preferably an C2-4 alkanoyloxy (e.g., acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy) . Said aryloxy is exemplified by phenoxy and 4- chlorophenoxy.
Examples of the optionally substituted thiol groups, mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include thiol group and substituted thiol groups having an appropriate substituent, particularly a substituent for use as a thiol group protecting group, such as alkylthio, alkenylthio, alkinylthio, aralkylthio and acylthio.
Said alkylthio is preferably Cι-10 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, nonylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio) .
Said alkenylthio is preferably C2-10 alkenylthio. Said alkinylthio is preferably C2-10 alkinylthio. Said aralkylthio is exemplified by phenyl-Cι-4 alkylthios (e.g., benzylthio, phenethylthio) .
Said acylthio is preferably a C2-4 alkanoylthio (e.g., acetylthio, propionylthio, n-butyrylthio, isobutyrylthio) . Examples of the optionally esterified carboxyl groups mentioned as substituents for the hydrocarbon residue and heterocyclic group, each represented by R or Z1, include carboxyl group, groups resulting from binding of a carboxyl group and an C1-6 alkyl group (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl. tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl) , groups resulting from binding of a carboxyl group and an C3-.6 alkenyl group, (e.g., allyloxycarbonyl, crotyloxycarbonyl, 2-pentenyloxycarbonyl and 3-hexenyloxycarbonyl) , and groups resulting from binding of a carbonyl group and an aralkyl group (e.g., benzyloxycarbonyl and phenethyloxycarbonyl) .
In the above formula (I), the substituent on the hydrocarbon residue and heterocyclic group, each represented by R or Z1, may optionally have further one or more, preferably 1 to 3, substituents at any substitutional positions. Examples of such substituents include Cι_χo lower alkyl groups, C2-10 lower alkenyl groups, C2-10 lower alkinyl groups, C3-7 cycloalkyl groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, aralkyl groups (e.g., aryl-Cι-6 alkyl), amino groups, N-mono-substituted amino groups, N,N-di-substituted amino groups, amidino groups, acyl groups, carbamoyl groups, N-mono-substituted carbamoyl groups (e.g., methylcarbamoyl, ethylcarbamoyl, phenylcarbamoyl) , N,N-di- substituted carbamoyl groups (e.g., N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, piperidinocarbamoyl, morpholinocarbamoyl, etc.), sulfamoyl groups, N-mono- substituted sulfamoyl groups (e.g., methylsulfamoyl, ethylsulfamoyl, phenylsulfamoyl, p-toluenesulfamoyl) , N,N- di-substituted sulfamoyl groups (e.g., N,N- dimethylsulfamoyl, N-methyl-N-phenylsulfamoyl, piperidinosulfamoyl, morpholinosulfamoyl, etc.), carboxyl groups, Cι-10 lower alkoxycarbonyl groups (e.g., methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, sec- butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbpnyl) , hydroxyl groups, Cχ_ιo lower alkoxy groups, C2-10 lower alkenyloxy groups, C3-.10 cycloalkyloxy groups, lower alkylthio groups, aralkylthio groups, arylthio groups, sulfo groups, cyano groups, azide groups, halogen atoms, nitro groups and nitroso groups. These substituents are exemplified by the same substituents as those for the hydrocarbon residue and heterocyclic group, each represented by R or Z1.
In the above formula (I), provided that R is -CH2-X1- Z1, the optionally substituted amino group for Z* is represented by -N(R1)(R2) (R1 and R2, whether identical or not, represent a hydrogen atom, an optionally substituted hydrocarbon residue, or an optionally substituted heterocyclic group; or R1 and R2 may bind together to form a ring) .
The optionally substituted hydrocarbon residue or optionally substituted heterocyclic group for R1 or R2 is exemplified by the same optionally substituted hydrocarbon residues or optionally substituted heterocyclic group as those mentioned to exemplify the group for R above.
The hydrocarbon residue and heterocyclic group, each represented by R1 or R2, may have 1 to 3 substituents at any substitutional positions on the chain or the ring thereof. Such substituents are exemplified by the same substituents as those for the hydrocarbon residue and heterocyclic group for R. These substituents on the hydrocarbon residue and heterocyclic group for R1 or R2 may have 1 or more, preferably 1 to 3, substituents at any substitutional positions. Examples of such substituents include Cι-10 lower alkyl groups, C2-10 lower alkenyl groups, C2-10 lower alkinyl groups, C3..7 cycloalkyl groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, aralkyl groups, amino groups, N-mono- substituted amino groups, N,N-di-substituted amino groups, amidino groups, acyl groups, carbamoyl groups, N-mono- substituted carbamoyl groups, N,N-di-substituted carbamoyl groups, sulfamoyl groups, N-mono-substituted sulfamoyl groups, N,N-di-substituted sulfamoyl groups, carboxyl group, lower Cι-10 alkoxycarbonyl groups, hydroxyl group, lower Cι_ιo alkoxy groups, lower C2-10 alkenyloxy groups, c 3-8 cycloalkyloxy groups, aralkyloxy groups, aryloxy groups, mercapto groups, lower Cι_6 alkylthio groups, aralkylthio groups, arylthio groups, sulfo groups, cyano groups, azide groups, nitro groups, nitroso groups and halogens. These substituents are exemplified by the same substituents as those for the hydrocarbon residue and heterocyclic group, each represented by R.
R1 and R2 may bind together to form a ring; such -NfR1)^2) rings include 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, 1-piperidinyl, 1-piperazinyl, 4- morpholinyl, 4-thiomorpholinyl, homopiperazin-1-yl, 1,2,4- triazol-1-yl, 1,3,4-triazol-l-yl, pyrazol-1-yl, imidazol-1- yl, 1,2,3-triazol-l-yl, l,2,3-triazol-2-yl, tetrazol-1-yl, benzimidazol-1-yl, indol-1-yl and lH-indazol-1-yl.
The optionally oxidized sulfur atom, represented by X, is exemplified by thio group, sulfinyl group and sulfonyl group, with preference given to the thio group.
In the above formula (I), rings A and B may each have a substituent. Such substituents include halogen atoms, nitro groups, optionally substituted Cι_ιo alkyl, C2-10 alkenyl, C2-10 alkinyl groups, optionally substituted hydroxyl groups, optionally substituted thiol groups, optionally substituted amino groups, optionally substituted acyl groups (e.g., Cι_ιo alkanoyl, C2-10 alkenoyl, C2-10 alkinoyl groups etc.), optionally esterified carboxyl groups, and optionally substituted aromatic ring groups.
Examples of the halogens mentioned as substituents for rings A and B include fluorine, chlorine, bromine and iodine, with preference given to fluorine and chlorine. Examples of the optionally substituted Cι-10 alkyl groups mentioned as substituents for rings A and B, may be linear Cι-10 alkyl, branched C3-10 alkyl or C3-10 cyclic alkyl, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Examples of the optionally substituted hydroxyl groups mentioned as substituents for rings A and B, include the hydroxyl group and substituted hydroxyl groups having an appropriate substituent, particularly a substituent for use as a hydroxyl group-protecting group, such as alkoxy, alkenyloxy, aralkyloxy and acyloxy, as well as aryloxy.
Said alkoxy is preferably a Cι-ιo alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy) .
Said alkenyloxy is exemplified by C2-10 alkenyloxys (e.g., allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2- cyclopentenyl ethoxy and 2-cyclohexenylmethoxy) . Said alkinyloxy is preferably a C2-10 alkinyloxy.
Said aralkyloxy is exemplified by phenyl-Cι_4 alkoxy (e.g., benzyloxy, phenethyloxy) .
Said acyloxy is preferably a C2-4 alkanoyloxy (e.g., acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy) . Said aryloxy is exemplified by phenoxy, 4- chlorophenoxy and so on.
Examples of the optionally substituted thiol groups mentioned as substituents for rings A and B, include thiol group and substituted thiol groups having an appropriate substituent, particularly a substituent for use as a thiol group-protecting group, such as alkylthio, alkenylthio, alkinylthio, aralkylthio, acylthio and arylthio.
Said alkylthio is preferably a Cι-10 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, nonylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio) .
Said alkenylthio is preferably a C2-10 alkenylthio. Said alkinylthio is preferably a C2-10 alkinylthio. Said aralkylthio is exemplified by phenyl-C_,_4 alkylthios (e.g., benzylthio, phenethylthio) .
Said acylthio is preferably a C2-4 alkanoylthio (e.g., acetylthio, propionylthio, n-butyrylthio, isobutyrylthio) . Said arylthio is exemplified by phenylthio, 4- chlorophenyl, and so on.
Examples of the optionally substituted amino groups mentioned as substituents for rings A and B, include amino group and substituted amino groups having 1 or 2 substituted selected from Cι-10 alkyl groups, C2-10 alkenyl groups, C2-10 alkinyl groups and aromatic groups and so on (e.g., methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, phenylamino, N-methyl-N-phenylamino) . Examples of the optionally substituted acyl groups mentioned as substituents for rings A and B, include formyl and the groups resulting from binding of a Cι_ιo alkyl group, C2-10 alkenyl group, C2-10 alkinyl group or aromatic group and a carbonyl group (e.g., acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2-cyclohexenecarbonyl, benzoyl, nicotinoyl). Examples of the optionally esterified carboxyl groups mentioned as substituents for rings A and B, include carboxyl group, groups resulting from binding of a carboxyl group and a Ci-β alkyl group (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl) , groups resulting from binding of a carboxyl group and a C3-6 alkenyl group (e.g., allyloxycarbonyl, crotyloxycarbonyl, 2-pentenyloxycarbonyl and 3-hexenyloxycarbonyl) , and groups resulting from binding of a carbonyl group and an aralkyloxy group, (e.g., benzyloxycarbonyl, phenethyloxycarbonyl etc.).
Examples of the optionally substituted aromatic ring groups mentioned as substituents for rings A and B, include Cβ-1 aromatic hydrocarbon residues (e.g., phenyl, naphthyl, anthryl etc.), and heterocyclic aromatic residues (e.g., pyridyl, furyl, thienyl, imidazolyl and thiazolyl).
Such substituents for rings A and B may each be present at any substitutional position of the ring thereof; 1 to 4 identical or different substituents may be present. Provided that substituents on ring A or B are mutually adjoining, they may bind together to form a ring represented by -(CH2)t~ or -0-(CH2)ι~0- (t is an integer from 3 to 5; 1 is an integer from 1 to 3); such rings include 5- to 7-membered rings formed in cooperation with carbon atoms of the benzene ring.
Preferably, ring A is substituted for by at least 1 alkoxy group, preferably Cι_3 alkoxy group, more preferably by at least 1 methoxy group. Still more preferably, ring A is substituted for by 2 identical or different alkoxy groups, preferably C1-3 alkoxy group, more preferably by methoxy groups. Most preferably, ring A is substituted for by 2 methoxy groups respectively at the 6- and 7-positions of the quinoline ring or quinazoline ring. Preferably, ring B is substituted for by at least 1 alkoxy group, preferably C1-.3 alkoxy group, more preferably at least 1 methoxy or isopropoxy group. Still more preferably, ring B is substituted for by 2 identical or different alkoxy groups, preferably C1-.3 alkoxy group. Most preferably, ring B is substituted for by a methoxy or isopropoxy group at the 3-position and by a methoxy group at the 4-position.
In the above formula (I), provided that Y is C-G, the optionally esterified carboxyl group for G is exemplified by carboxyl group, alkoxycarbonyl groups and aralkyloxycarbonyl group. The alkyl group in said alkoxycarbonyl groups is exemplified by Ci-β alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl).
The aralkyl group in said aralkyloxycarbonyl groups is an alkyl group having an aryl group as a substituent (aryl- alkyl group) . Said aryl group is exemplified by phenyl and naphthyl, each of which may have the same substituents as those for ring A above. Said alkyl group is preferably a lower Cι-6 alkyl group. Preferable aralkyl groups include benzyl, phenethyl, 3-phenylpropyl, (l-naphthyl)methyl and (2-naphthyl)methyl, with preference given to benzyl, phenetyl and others.
Provided that G is an amidated carboxyl group, it is represented by -CONfR1)^2) (R1 and R2 have the same definitions as those given above).
The acyl group for G in the above formula (I) is represented, for example, by the formula: -CO-R3 in which R3 is an alkyl group or an aryl group. Examples of the alkyl group for R3 include C1-5 alkyl groups (e.g., methyl, ethyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, etc.). Preferred examples of the alkyl group for R3 include methyl, butyl, isobutyl, pentyl, etc.. Examples of the aryl gorup for R3 includes a monocyclic or condensed polycyclic aromatic hydrocarbon group having 6 to 14 carbon atoms. Preferred examples of the aryl group for R3 include phenyl, naphthyl, anthryl, phenanthryl, etc.. In particular, phenyl, 1-naphthyl, 2-naphthyl, etc., are more preferred. Provided that G is hydroxyalkyl, the alkyl group of the hydroxyalkyl group for G includes the above alkyl groups represented by Ri or R2. Preferably, the hydroxyalkyl group is represented by the formula: -CH2OH or -CH(OH)-R3 in which R3 is an defined above. R3 in this formula is preferably methyl, ethyl, etc.. Provided that G is protected hydroxyalkyl, the protected hydroxy moiety may be the above substituted hydroxyl group as the substituent of the hydrocarbon group or heterocyclic group represented by R* or R2. Preferably, the protected hydroxyalkyl group is represented by the formula: -C^OCOR-i or -CH(OCOR-»)-R3 in which R3 is as defined above and R4 is an alkyl group, aralkyl group or aryl group each of which may optionally be substituted. The alkyl group for R4 includes, for example, Cχ-6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, etc.. The aralkyl group for R4 means, for example, a Cβ-14 aryl-Cι_4 alkyl group. Specific examples of the alkyl group in the aralkyl group include the above alkyl groups represented by R4. specific examples of the aryl group in the aralkyl group include phenyl, naphthyl, etc. Examples of the aralkyl group include benzyl, phenethyl, 3-phenylpropyl, (1- naphthy1)methyl, (2-naphthyl)methyl, etc.. The aryl group for R4 includes, for example, aryl group having 6 to 14 carbon atoms such as phenyl, naphthyl, etc..
In the above formula (I), provided that Y is C-G, R and G may bind together to form a 5-membered ring. Such a structure is represented by the following formula (II) or (III).
Figure imgf000023_0001
(ID (III)
In these formulas, R3 represents a hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted heterocyclic group; the other symbols have the same definitions as those given above.
In the above formulas (II) and (III), the optionally substituted hydrocarbon residue and optionally substituted heterocyclic group, represented by R3, are exemplified by the same ones mentioned to exemplify R and Z1 above.
In the above formula (I), Y is preferably C-G, with greater preference given to a Cι-6 alkoxycarbonyl group for G, and greatest preference given to an ethoxycarbonyl group for G. n in the above formula (I) is preferably 0. k in the above formula (I) is preferably 0.
Of the compounds represented by the formula (I), preference is given to those wherein Y is C-G (G is ethoxycarbonyl), R is -CH2-Z1, Z1 is 1,2,4-triazol-l-yl, the substituents for ring A are methoxy groups each present at the 6- and 7-position of the quinoline ring, each substituent for ring B is methoxy or isopropoxy group present at the 3-position and methoxy groups present at the 4-position thereof, n is 0, and k is 0.
Preferable examples of compounds represented by the formula (I) is
6,7-dimethoxy-9-phenylfuro[3,4-b]quinoline-l(3H)-one; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (1- methylimidazol-2-yl)thiomethyl]quinoline-3-carboxylate;
4-(3,4-dimethoxyphenyl)-2-(2-hydroxyethylthiomethyl)- 6,7-dimethoxyquinazoline;
4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (4-methyl- 1,2,4-triazol-3-yl)thiomethyl]quinazoline; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[2-(l- methylimidazol-2-yl)ethyl]quinoline-3-carboxylate; methyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3- methoxycarbonylquinoline-2-acetate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3-isopropoxy-4-methoxyphenyl)-6,7-dimethoxy- 2-(1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3-hydroxy-4-methoxyphenyl)-6,7-dimethoxy-2- (l,2,4-triazole-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 7-hydroxy-6-methoxy-4-(3,4-dimethoxyphenyl)-2- (1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-l-ylmethyl)quinoline-3-carboxylate 1-oxide; or ethyl 2-(N,N-diethylaminomethyl)-4-(3,4- dimethoxyphenyl)-6,7-dimethoxyquinoline-3-carboxylate.
The above compound (I) can be produced according to the production methods described in detail, for instance, in Japanese Patent Unexamined Publication (Kokai tokkyo koho) Nos. 306052/1994(EP-A-0567107), 118266/1995(EP-A- 0608870), 69890/1995(EP-A-0634169), 53419/1996(EP-A- 0686630) and W095/24394.
The salt of compound (I) for the present invention is preferably a pharmaceutically acceptable salt, exemplified by salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids and salts with basic or acidic amino acids.
Preferable salts with inorganic base include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salt and ammonium salt.
Preferable salts with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and N,N'-dibenzylethylenediamine.
Preferable salts with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid. Preferable salts with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
Preferable salts with basic amino acid include salts with arginine, lysine and ornithine. Preferable salts with acidic amino acid include salts with aspartic acid and glutamic acid. Amont these salts, sodium or patassium salts are most preferable.
The compound (I) or a salt thereof of the present invention may be a hydrate.
In the present invention, the pharmaceutical agent combined with a little slowly acting quinoline or quinazoline compound for the prophylaxis or therapeuticy of arthritis is what is called a rapidly acting anti- inflammatory analgesic agent which clinically suppresses inflammation and accompanying pain in 30 minutes or in 2 to 3 days, at latest within 1 week, after administration.
As such, rapidly acting anti-inflammatory analgesics can be classified in various manners according to chemical structure, action etc., but those advantageous for use in the present invention include ® cyclooxygenase inhibitors, (D central analgesics, D steroids, and (D anti- inflammatory enzyme agents.
Cyclooxygenase inhibitors are compounds that suppress cyclooxygenase 1 and/or cyclooxygenase 2; preferable examples include the following compounds and salts thereof.
Salicylic acid derivatives possessing anti- inflammatory analgesic activity, such as aspirin; pyrazolone derivatives possessing anti-inflammatory analgesic activity, such as antipyrine; phenylbutazone, oxybutazone, sulfinpyrazone, acemetacin, alclofenac, alminoprofen, anfenac, ampiroxicam, butybufen, calprofen, dichlofenac, diflunisal, droxicam, etodolac, fenbufen, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, indomethacin, indomethacin farnesil ester, ketoprofen, ketorolac, loxoprofen, mefenamic acid, meclofenamate, meloxicam, nabumetone, naproxen, oxaprozin, pirazolac, piroxicam, pranoprofen, proglumetacin, sulindac, tenidap, tenoxicam, tiaprofenic acid, ticlopidine, tolmetin, tolfenamic acid, ximoprofen, zaltoprofen, nimesulide, fulosulide, 3-formylamino-7-methylsulfonylamino-6-phenoxy- 4H-l-benzopyran-4-one, N-[2-cyclohexyloxy-4- nitrophenylJmethanesulfonamide, dihydro-4-[ [3,5-bis(1,1- dimethylmethyl)-4-hydroxyphenylJmethylene]-2-methyl-2H-l,2- oxazin-3(4H)-one, 1-[4-(methylsulfonyl) phenyl]-3-tolfluoromethyl-5-(4-fluorophenyl)-lH-pyrazole, 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl) benzene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl) phenyl]thiophene, and 5-methanesulfonamide-6-(2,4- difluorophenylthio)-l-indanone. Also preferable are the compounds described in
International Patent Publication Nos. W095/15315, W095/ 15316, W095/15317 and W095/15318 and salts thereof. More specifically, preferable compounds include the compounds described in claim 16 for W095/15315 above [e.g., l-[(4- alkylsulfonyl)phenyl]-3-substitutional-5-substitutional-lH- pyrazole derivatives], i.e.,
1-[4-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-3- trifluoromethyl-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(4-chlorophenyl)-3- (trifluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-bromophenyl)-3- (trifluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-iodophenyl)-3- (trifluoromethyl)-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(phenyl)-3- (trifluoromethyl)pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-3- (chlorodifluoromethyl)-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(4-chlorophenyl)-3- chlorodifluoromethyl)-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(4-bromophenyl)-3-
(chlorodifluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-iodopheny1)-3-
(chlorodifluoromethyl)-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(phenyl)-3-
(chlorodifluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-3-
(difluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-chlorophenyl)-3- (difluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-bromophenyl)-3-
(difluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-iodopheny1)-3-
(difluoromethyl)-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(phenyl)-3-
(difluoromethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(fluorophenyl)-3-
(pentafluoroethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-chlorophenyl)-3- (pentafluoroethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-bromophenyl)-3-
(pentafluoroethyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-iodopheny1)-3- pentafluoroethyl-lH-pyrazole, 1-[4-(methylsulfonyl)phenyl]-5-(phenyl)-3-
(pentafluoroethyl)pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-3-
(heptafluoropropyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-chlorophenyl)-3- (heptafluoropropyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-bromophenyl)-3-
(heptafluoropropyl)-lH-pyrazole,
1-[4-(methylsulfonyl)phenyl]-5-(4-iodopheny1)-3-
(heptafluoropropyl)-lH-pyrazole, and 1-[4-(methylsulfonyl)phenyl]-5-(phenyl)-3-
(heptafluoropropyl)-lH-pyrazole; the compounds described in claim 7 for W095/15316 above
[e.g., 4-(lH-pyrazol-l-yl)benzenesulfonamide derivatives that may be substitutional at the 3- and 5-positions], i.e. , ethyl l-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)- lH-pyrazole-3-carboxylate, ethyl 1-[4-(aminosulfonyl)phenyl]-5-( -methylphenyl)- lH-pyrazole-3-carboxylate, isopropyl 1-[4-(aminosulfonyl)phenyl]-5-(4- chlorophenyl)-lH-pyrazole-3-carboxylate,
N-[4-(methylphenyl]-1-[4-(aminosulfonyl)phenyl)-5-(4- fluorophenyl)-lH-pyrazole-3-carboxamide,
N-[3-chlorophenyl]-1-[4-(aminosulfonyl)phenyl]-5-(4- fluorophenyl)-lH-pyrazole-3-carboxamide, N-[3-fluorophenyl]-1-[4-(aminosulfonyl)phenyl]-5-(4- fluorophenyl)-lH-pyrazole-3-carboxamide,
N-[3-fluorophenyl]-1-[4-(aminosulfonyl)phenyl]-5-(4- chlorophenyl)-lH-pyrazole-3-carboxamide, phenylmethyl N-[ [1-[4-(aminosulfonyl)phenyl]-5-(4- chlorophenyl)-lH-pyrazol-3-yl]carbonyl]glycinate,
4-[5-(4-bromophenyl)-3-cyano-lH-pyrazol-l- yl]benzenesulfonamide,
4-[3-cyano-5-(4-fluorophenyl)-lH-pyrazol-l- yl]benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-cyano-lH-pyrazol-l- yl]benzenesulfonamide,
4-[3-cyano-5-(4-methoxyphenyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[3-cyano-5-(4-methylphenyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[3-cyano-5-(4-methylthiophenyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(5-chloro-4-methoxyphenyl)-3-cyano-lH-pyrazol-1- yl]benzenesulfonamide, 4-[5-(5-bromo-4-methoxyphenyl)-3-cyano-lH-pyrazol-l- yljbenzenesulfonamide. 4-[3-cyano-5-phenyl-lH-pyrazol-l- yi ]benzenesulfonamide,
4- [4-chloro-5-[4-fluorophenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-chloro-5-[4-chlorophenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-bromo-5-(4-chlorophenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-chloro-5-phenyl-lH-pyrazol-l- yi ]benzenesulfonamide,
4- [4-chloro-5-(3,5-dichloro-4-methoxyphenyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4- [4-bromo-5-(4-methylphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-chloro-5-(4-methylphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-chloro-5-(3-chloro-4-methoxyphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- 14-chloro-5-(4-methoxyphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-bromo-5-(4-methoxyphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-cyano-5-(4-methoxyphenyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)- 1H -pyrazol-1-yl]benzenesulfonamide, 4- [4-ethyl-5-phenyl-3-(trifluoromethyl)-lH-pyrazol-1- yi ]benzenesulfonamide,
4- [4-methyl-5-phenyl-3-(trifluoromethyl)-lH-pyrazol- 1-yl]benzenesulfonamide, 4- [5-(4-methoxyphenyl)-4-methyl-3-{trifluoromethyl)- 1H -pyrazol-1-yl]benzenesulfonamide, 4- [5-(4-chlorophenyl)-4-methyl-3-(trifluoromethyl)- 1H -pyrazol-1-yl]benzenesulfonamide, 4- [5-(4-chlorophenyl)-4-ethyl-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide, 4-[4-ethyl-5-(4-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[4-ethyl-5-(4-methoxy-3-methylphenyl)-3-
(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[4-ethyl-5-(4-methoxyphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[4-ethyl-5-(3-fluoro-4-chlorophenyl)-3-
(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(4-fluorophenyl)-4-methyl-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[4-methyl-5-(4-methylphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide, 4-[4-fluoro-5-phenyl-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[4-bromo-5-(4-chlorophenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[4-chloro-5-(3,5-dichloro-4-methoxyphenyl)-3- (difluoromethyl)-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-chloro-3-(difluoromethyl)-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-bromo-3-(difluoromethyl)-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-chloro-3-(difluoromethyl)-5-(4-methoxyphenyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[4-(chloro-3-cyano-5-phenyl-lH-pyrazol-1- yl]benzenesulfonamide, 4-[4-chloro-5-(4-chlorophenyl)-3-cyano-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-chloro-3-cyano-5-(4-fluorophenyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[4-bromo-3-cyano-5-(4-fluorophenyl)-lH-pyrazol-1- yljbenzenesulfonamide. 4-[4-bromo-3-cyano-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide, ethyl [1-(4-aminosulfonylphenyl)-4-bromo-5-(4- chlorophenyl)-lH-pyrazol-3-yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-phenyl- lH-pyrazol-3-yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(4- chlorophenyl)-lH-pyrazol-3-yl]carboxylate, ethyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(4- chlorophenyl)-lH-pyrazol-3-yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(4- fluorophenyl)-lH-pyrazol-3-yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-bromo-5-(4- fluorophenyl)-lH-pyrazol-3-yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(3- chloro-4-methoxyphenyl)-lH-pyrazol-3- yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(3,5- dichloro-4-methoxyphenyl)-lH-pyrazol-3- yl]carboxylate, methyl [1-(4-aminosulfonylphenyl)-5-(3-bromo-4- methoxyphenyl)-4-chloro-lH-pyrazol-3- yl]carboxylate,
4-[4-chloro-3-isopropyl-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-chloro-3-methyl-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide,
4-[4-chloro-3-hydroxymethyl-5-phenyl-lH-pyrazol-l- yl]benzenesulfonamide, 4-[4-chloro-5-(chlorophenyl)-3-hydroxymethyl-lH- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-phenyl-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-IH-pyrazol- 1-yl]benzenesulfonamide,
4-[5-(4-cyanophenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(2,4-difluorophenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide,
4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-IH-pyrazol
-1-yl]benzenesulfonamide,
4-[5-(3,4-dichlorophenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide, 4-[5-(4-bromophenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(2,4-dichlorophenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-chlorophenyl)-3-(trifluoromethyl)-lH-pyrazol- 1-yl]benzenesulfonamide,
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol- l-yl]benzenesulfonamide,
4-[5-(2-chlorophenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide, 4-[5-(2-fluorophenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(4-aminophenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(2-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol- 1-yl]benzenesulfonamide,
4-[5-(4-fluoro-2-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide, 4-[5-(4-ethoxyphenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(3,5-dimethylphenyl-4-methoxy)-3-
(trifluoromethyl)-lH-pyrazol-l-yl]benzenesulfonamide,
4-[5-(3-fluorophenyl)-3-(trifluoromethyl)-lH-pyrazol- 1-yl]benzenesulfonamide,
4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-methylthiophenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chloro-3-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide,
4-[5-(4-ethylphenyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(2,4-dimethylphenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide, 4-[5-(2-methoxyphenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(4-methoxy-3-methylphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-bromo-4-methylthiophenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-{3-chloro-4-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3,4-dimethoxyphenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide, 4-[5-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-chloro-4-methoxy-5-methylphenyl)-3-
(trifluoromethyl)-lH-pyrazol-l- yl]benzenesulfonamide, 4-[5-(3-ethyl-4-methoxyphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-fluoro-2-methoxyphenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-methoxy-3-(3-propinyl)phenyl)-3- (trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(3,5-dichloro-4-methoxyphenyl)-3-
(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide, 4-[5-(3-chloro-4-fluorophenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide. 4-[5-(3-fluoro-4-methylthiophenyl)-3-
(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(3-methyl-4-methylthiophenyl)-3- (trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(3-chloro-4-methylthiophenyl)-3-
(trifluoromethyl)-lH-pyrazol-1- yljbenzenesulfonamide, 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-15-(4-(N-methylamino)phenyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide,
4-[5-(3-amino-4-methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chlorophenyl)-3-(difluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide, 4-[5-(4-methylthiophenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-methylphenyl)-3-(difluoromethyl)-lH-pyrazol- l-yl]benzenesulfonamide,
4-[5-phenyl-3-(difluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(4-methoxyphenyl)-3-(difluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide, 4-15-(4-chlorophenyl)-3-(difluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(2-fluoro-4-methoxyphenyl)-3-(difluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-chloro-4-methylphenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chloro-3-methylphenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3,4-dimethoxyphenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(3,5-dichloro-4-methoxyphenyl)-3-
(difluoromethyl)-lH-pyrazol-1- yljbenzenesulfonamide,
4-[5-(3,5-difluoro-4-methoxyphenyl)-3- (difluoromethyl)-lH-pyrazol-l- yl]benzenesulfonamide,
4-[5-(2-methoxyphenyl)-3-(difluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(3-bromo-4-methoxyphenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-methylsulfonylphenyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-15-(4-chlorophenyl)-3-(heptafluoropropyl)-lH-pyrazol-1- yl]benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(chloro-difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chlorophenyl)-3-(pentafluoroethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-fluorophenyl)-3-(3-hydroxypropyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(3,5-dichloro-4-methoxyphenyl)-3-(3- hydroxypropyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(3-chloro-4-methoxyphenyl)-3-(chloromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(4-chlorophenyl)-3-(cyanomethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[3-(chloro-difluoromethyl)-5-(3-fluoro-4- methoxyphenyl)-lH-pyrazol-1- yl]benzenesulfonamide, ethyl 3-[1-(4-aminosulfonylphenyl)-5-(phenyl)-IH- pyrazol-3-yl]2-cyano-2-propenoate,
4-[5-(phenyl)-3-(fluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(5-bromo-2-thienyl)-3-(difluoromethyl)-lH- pyrazol-1-yl]benzenesulfonamide,
4-[5-(5-chloro-2-thienyl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(1-cyclohexenyl)-3-(difluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide, 4-[5-(1-cyclohexyl)-3-(difluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(1,4-benzodioxan-6-yl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[3-(difluoromethyl)-5-(4-methylcyclohexyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(2-benzofuranyl)-3-(difluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(1,3-benzodioxol-5-yl)-3-(difluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide, 4-[5-(2-benzofuryl-1)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(5-bromo-2-thienyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide,
4-[5-(5-chloro-2-thienyl)-3-(trifluoromethyl)-1H- pyrazol-l-yl]benzenesulfonamide,
4-[5-(5-indanyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(5-methyl-2-thienyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide, 4-[5-(2,3-dihydrobenzofuran-2-yl)-3-(trifluoromethyl)- lH-pyrazol-1-yl]benzenesulfonamide,
4-[5-(1-cyclohexenyl)-3-(trifluoromethyl)-lH-pyrazol-
1-yl]benzenesulfonamide,
4-[5-(1,2,3,4-tetrahydronaphth-5-yl)-3- (trifluoromethyl)-lH-pyrazol-l- yl]benzenesulfonamide, 4-[5-(2-benzothienyl)-3-(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide,
4-[5-(3,4-dihydro-2H-l-benzothiopyran-7-yl)-3-
(trifluoromethyl)-lH-pyrazol-l- yl]benzenesulfonamide,
4-[5-(4-methyl-l,3-benzodioxol-6-yl)-3-
(trifluoromethyl)-lH-pyrazol-1- yl]benzenesulfonamide, and
4-[5-(4-methyl-l,3-benzodioxol-5-yl)-3-(trifluoromethyl) lH-pyrazol-1- yl]benzenesulfonamide;
4-(4-fluorophenyl)-5-[4-methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-chlorophenyl)-5-.4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-{4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-iodophenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole, 5-[4-(methylsulfonyl)phenyl)-1,4-diphenyl-3-
(trifluoromethyl)-lH-pyrazole,
4-(4-(methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-(methylthiophenyl)-5-[4-(methylsulfonyl)phenyl]- l-phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-(methylsulfinylphenyl)-5-[4-
(methylsulfonyl)phenyl]-l-phenyl-3-(trifluoromethyl)-1H- pyrazole,
4-(4-hydroxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole, 4-(4-aminophenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole, 4-(4-N-methylaminophenyl)-5-[4-(methylsulfonyl)phenyl]-1- phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-N,N-dimethylaminophenyl)-5-[4-
( ethylsulfonyl)phenyl]-l-phenyl-3-(trifluoromethyl)-1H- pyrazole,
4-(4-trifluoromethylphenyl)-5-[4-
(methylsulfonyl)phenyl]-l-phenyl-3-(trifluoromethyl)-1H- pyrazole,
4-(4-acetamidophenyl)-5-[4-(methylsulfonyl)phenyl]- l-phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-[N-acetylamino]methylphenyl)-5-[4-
(methylsulfonyl)phenyl]-l-phenyl-3-(trifluoromethyl)-1H- p razole, l-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-chlorophenyl)-5-[4-(methylsulfonylJphenyl]-4-phenyl-3-
(trifluoromethyl)-lH-pyrazole, l-(4-bromophenyl)-5-[4-(methylsulfonylJphenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole, 1-(4-iodophenyl)-5-[4-(methylsulfonyl)phenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-methylphenyl)-5-[4-(methylsulfonylJphenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-methylthiophenyl)-5-[4-(methylsulfonyl)phenyl]- 4-phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-hydroxyphenyl)-5-[4-(methylsulfonyl)phenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-methoxyphenyl)-5-[4-(methylsulfonylJphenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole, 1-(4-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole,
1-(4-aminophenyl)-5-[4-(methylsulfonyl)phenyl]-4- phenyl-3-(trifluoromethyl)-lH-pyrazole, 1-(4-N-methylaminophenyl)-5-[4- (methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1H- pyrazole. 1-(4-N,N-dimethylaminophenyl)-5-[4-
(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-lH- pyrazole,
1-(4-trifluoromethylphenyl)-5-[4- (methylsulfonylJphenyl]-4-phenyl-3-(trifluoromethyl)-1H- pyrazole,
1-(4-acetamidophenyl)-5-[4-(methylsulfonyl)phenyl]-
4-phenyl-3-(trifluoromethyl)-lH-pyrazole,
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-l- phenyl-3-(difluoromethyl)-lH-pyrazole,
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-l-pheny1- lH-pyrazole,
4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-l- phenyl-3-(methyl)-lH-pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1- pheny1-3-(cyano)-lH-pyrazole,
1,4-bis(4-fluorophenyl)-5-[4-
(methylsulfonylJphenyl]-3-(trifluoromethyl)-lH-pyrazole,
5-[4-(methylsulfonyl)phenyl]-1,4-diphenyl]-3- (difluoromethylJ-lH-pyrazole,
4-[4-(4-fluorophenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazole-5-yl)benzenesulfonamide,
4-[4-(4-chlorophenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide, 4-[4-(4-bromophenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-iodophenyl)-l-phenyl-3-(trifluoromethyl)-1H- pyrazol-5-yl]benzenesulfonamide, l,4-diphenyl-3-(trifluoromethyl)-lH-pyrazol-5- yl]benzenesulfonamide,
4-[4-(4-methylphenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-methylthiophenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide, 4-[4-(4-methylsulfonylphenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide, 4-[4-(4-hydroxyphenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-methoxyphenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide, 4-[4-(4-nitrophenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-aminophenyl)-l-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-N-methylaminophenyl)-l-phenyl-3- (trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-N,N-dimethylaminophenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-trifluoromethylphenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide, 4-[4-(4-acetamidophenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-[N-acetylamino]methylphenyl)-l-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-fluorophenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-chlorophenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-bromophenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide, 4-[1-(4-iodophenyl)-4-phenyl-3-(trifluoromethyl)-1H- pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-methylphenyl)-4-phenyl-3-{trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-methylthiophenyl)-4-phenyl-3- (trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-hydroxyphenyl)-4-phenyl-3-( rifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-methoxyphenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide, 4-[1-(4-nitrophenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide, 4-[1-(4-aminophenyl)-4-phenyl-3-(trifluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-N-methylaminophenyl)-4-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide, 4-[1-(4-N,N-dimethylaminophenyl)-4-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-trifluoromethylphenyl)-4-phenyl-3-
(trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[1-(4-acetamidophenyl)-4-phenyl-3- (trifluoromethyl)-lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-fluorophenyl)-l-phenyl-3-(difluoromethyl)- lH-pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-fluorophenyl)-l-phenyl-lH-pyrazol-5- yl]benzenesulfonamide, 4-[4-{4-fluorophenyl)-l-phenyl-3-(methyl)-1H- pyrazol-5-yl]benzenesulfonamide,
4-[4-(4-fluorophenyl)-l-phenyl-3-(cyano)-lH-pyrazol-
5-yl]benzenesulfonamide,
4-[1 ,4-bis(4-fluorophenyl)-3-(trifluoromethyl)-1H- pyrazol-5-yl]benzenesulfonamide, and
4-[1,4-diphenyl-3-(difluorophenyl)-lH-pyrazol-5- yl]benzenesulfonamide.
Also preferable are the compounds as cycloxygenase inhibitors described in Japanese Patent Unexamined Publication (Kokai tokkyo koho) No. 246997/1993 (EP-
0554829) or salts thereof. Those compounds described in said Kokai tokkyo koho are exemplified by the formula (IV) below.
Figure imgf000042_0001
In the above formula (IV), R5 is aryl which is substituted with substituent(s) selected from the group consisting of Cχ-6 alkylthio, cyclo Cι_6 alkyl, hydroxy, hydroxy Cι-6 alkyl, cyano, Ci-β alkylenedioxy, acyl, acyloxy, aryloxy and Ci-β alkoxy optionally substituted with acyl or Cι-6 alkoxy; R6 is halogen, halo Cι-6 alkyl, cyano or acyl, and
R7 is aryl substituted with nitro, hydroxy, C\-_. alkoxy, Ci 6 alkylthio, Cχ-e alkylsulfinyl or Ci-β alkylsulfonyl; provided that when R? is aryl substituted with nitro, hydroxy or lower alkoxy, then R5 is aryl substituted with Cι-6 alkylthio, Cχ-6 alkylsulfinyl or Cι_6 alkylsulfonyl. In the above formula (IV), 5 is phenyl which is substituted with substituent(s) selected from the group consisting of hydroxy, hydroxy Cι_g alkyl, cyano, C_.-6 alkylenedioxy, acyl, acyloxy, aryloxy and Cι_6 alkoxy optionally substituted with acyl or Cι-6 alkoxy, and preferably phenyl substituted with cyano, Cι-6 alkanoyl or Cι_6 alkoxy, and more preferably phenyl substituted with cyano or methoxy.
In the above formula (IV), R7 is phenyl substituted with Cι-6 alkylthio, Cι-6 alkylsulfinyl or Cι-6 alkylsulfonyl, preferably phenyl substituted with methylthio, methylsulfinyl or methylsulfonyl.
In the above formula (IV), R6 is halogen or halo Ci-β alkyl, preferably bromine, difluoromethyl or trifluoromethyl.
Preferable examples of compounds represented by the formula (IV) is 3-(difluoromethyl)-l-(4-methoxyphenyl)-5- [4-(methylsulfonyl)phenyl]pyrazole, or 3-(difluoromethyl)- 1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole. Central analgesics generically refer to narcotic or non-narcotic analgesics; preferable examples include the following compounds and salts thereof.
Morphine, codeine, ethylmorphine, oxycodeine, dihydrocodeine, pethidine, fentanyl and pentazocine. Steroids refer to all corticosteroids possessing anti- inflammatory activity; preferable examples include the following compounds and salts thereof.
Betamethasone, dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, triamcinolone and paramethasone.
Anti-inflammatory enzyme agents generically refer to proteins possessing acute inflammation-suppressing activity and/or analgesic activity; preferable examples include the following.
Bromelins, lysozyme, promelase, pronase, serrapeptase, streptokinase, chymotrypsin and amylase.
These anti-inflammatory analgesics may be in the form of pharmaceutically acceptable salts, as with compound (I). The pharmaceutical composition of the present invention, comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic, can be administered orally or non-orally in the form of granules, powders, tablets, capsules, syrups, suppositories, injectable preparations, emulsions, elixirs, suspensions, solutions etc., as prepared separately or simultaneously by mixing with physiologically acceptable carriers, excipients, binders, diluents etc. When active ingredients are separately prepared, the resulting separate preparations can be administered in the form of a mixture with diluents etc. prepared freshly at the time of use; however, separate preparations may be administered to the same subject separately, simultaneously or at intervals. The pharmaceutical composition of the present invention can be prepared as various dosage forms in accordance with ordinary methods. In the present specification, the term "non-oral" encompasses subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection and drip infusion. Preparations for injection, e.g., aqueous or oily suspensions for aseptic injection, can be prepared by methods known to those skilled in the art, using an appropriate dispersing agent or a wetting agent and a suspending agent. The preparation for aseptic injection may be a solution or suspension permitting aseptic injection in a diluent or solution that is non-toxic and administrable non-orally, such as an aqueous solution. Useful vehicles or solvents include water. Ringer's solution and isotonic saline. Aseptic nonvolatile oils can also be used as solvents or suspending media.
To this end, any nonvolatile oils or fatty acids can be used, including natural, synthetic or semi-synthetic fatty oils and fatty acids, and natural, synthetic or semi- synthetic mono-, di- or tri-glycerides. Suppositories for rectal administration can be produced by mixing the drug and an appropriate non- irritative excipient that is solid at normal temperature but liquid at gut temperature and melts to release the drug in the rectum, such as cocoa butter or polyethylene glycol. Solid dosage forms for oral administration include powders, granules, tablets, pills and capsules, as mentioned above. In such dosage forms, the active ingredient compound can be mixed with at least 1 additive selected from the group consisting of sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starches, agar, alginates, chitins, chitosans, pectins, gum tragacanth, gum arabic, gelatins, collagens, casein, albumin, and synthetic or semi-synthesis polymers and glycerides. As usual, these dosage forms can contain additional additives, including inert diluents, lubricants such as magnesium stearate, preservatives such as parabens and sorbic acid, antioxidants such as ascorbic acid, a- tocopherol and cysteine, disintegrating agents, binders, thickening agents, buffers, sweetening agents, flavoring agents and perfumes. Tablets and pills can also be produced with enteric coating. Liquid preparations for oral administration include pharmaceutically acceptable emulsions, syrups, elixirs, suspensions and solutions, and may contain inert diluents in common use in the relevant art, such as water. Although a daily dose of each pharmaceutical agent can be chosen appropriately, according to patient age, body weight, symptoms, administration time, dosage form, administration method, combination of each pharmaceutical agent etc., it can be chosen over the range of 5-1000 mg preferably 10-200 mg, per adult person, the likely clinical dose range for oral administration, and over the range of 0.1-100 mg, preferably 1-100 mg per adult person for non- oral adminstration in the case of quinoline or quinazoline compound for prophylaxis or therapy of arthritis; and can be increased or decreased as appropriate on the basis of the likely clinical dose range for oral administration in the case of rapidly acting anti-inflammatory analgesics such as φ cyclooxygenase inhibitors, φ central analgesics, φ steroids, and (D anti-inflammatory enzyme agents. In the case of oral or non-oral administration, the dose can be chosen as appropriate according to the situation on the basis of the likely clinical dose range when individual drugs are used singly. φ In the case of cyclooxygenase inhibitors, the dose for oral administration can be chosen over the range of 1- 5000 mg, preferably 25-4500 mg per adult person, for example, 1000-4500 mg for aspirin, 50-150 mg for indomethachin, 25-75 mg for diclofenac, 60-180 mg for loxoprofen, and the dose for non-oral administration can be chosen over the range of 0.2-200 mg, preferably 1-100 mg per adult person. φ In the case of central analgesics, the dose for oral administration can be chosen over the range of 1-1000 mg, preferably 5-300 mg per adult person, for example, 10-60 mg for morphine, and the dose for non-oral administration can be chosen over the range of 0.1-300 mg, preferably 0.5-100 mg per adult person for example, 5-60 mg, for morphine. φ In the case of steroids, the dose for oral administration can be chosen over the range of 0.1-400 mg, preferably 0.5-100 mg per adult person, for example, 5-100 mg, for prednisolone, and 0.5-10 mg for dexamethasone, and the dose for non-oral administration can be chosen over the range of 0.1-100 mg, preferably 0.5-25 mg per adult person for example, 5-25 mg for prednisolone, 0.5-2.5 mg for dexamethasone.
(D In the case of anti-inflammatory enzyme agents, the dose for oral administration can be chosen over the range of 5-40 mg, per adult person.
Appropriate administration frequency is 1 to 3 times daily. A pharmaceutical composition of the present invention comprising a combination of the agents mentioned above has low toxity.
Example 1 Action on rat adjuvant arthritis
Male Lewis rats (7 weeks of age), 6 per group, were sensitized by intradermally injecting 0.05 ml of Freund's complete adjuvant (0.5% liquid paraffin suspension of dead tubercle bacillus cells) to the right hind leg paw. Five to 6 times weekly from just before sensitization (0 day) to 30 days, the ethyl ester of 4-(3,4-dimethoxyphenyl)-6,7- dimethoxy-2-(1,2,4-triazol-l-ylmethyl)quinoline-3- carboxylic acid (Compound A) (3.13 mg/kg) and indomethacin (0.25 mg/kg), in suspension in 0.5% methyl cellulose, singly or concomitantly, were orally administered. Just before sensitization (0 day) and at 14 and 28 days, the left hind leg paw volume was measured to obtain the paw swelling suppression rate, in comparison with non- sensitized rats. Body weight was measured just before administration; the body weight increase rate (%) was obtained in comparison with non-sensitized rats. The results are shown in mean ± standard error for each group (N = 6) and compared by Student's t-test at a significance level of < 5%.
As shown in Table 1, concomitant administration of Compound A and indomethacin showed more potent action in terms of edema suppression and body weight increase, in comparison with either drug administered alone.
Particularly, with respect to the action in terms of edema suppression, which is a direct index of an anti- inflammatory action, the result of concomitant administration of compound A and indomethacin at 28 days showed a remarkable effect beyond the sum effect of both agents.
Table 1
Swelling Suppres¬ Body Weight In¬
Manner of sion Rate (%) crease Rate (%)1) Administration
14 Days 28 Days 14 Days 30 Days
Compound A 3.13 42 43 14* 24*
Indomethacin 0.25 38* 69* 11* 10
Concomitant use 64*Φ 95*ΦO 15* 31*Φ
1)
(Agent-administered rats) - (Sensitized control rats) x 100
(Normal control rats) - (Sensitized control rats)
*: P < 0.05 vs control group;
Φi P < 0.05 vs indomethacin administration group
Q: P < 0.05 vs compound A administration group
As seen in the table, concomitant use of Compound A and indomethacin showed greater swelling-suppressing action, in comparison with the single use of Compound A or indomethacin, resulting in markedly increased body weight. Especially, the effect of concomitant use of two compounds on the paw swelling at 28 days is additive or more. Industrial Applicability
The combined pharmaceutical provided by the present invention exhibits excellent rapidly acting and sustained anti-inflammatory analgesic action against arthritis, especially rheumatoid arthritis, with very low prevalence of side effects even in chronic administration, provided that drug combination, administration method, dose etc. are appropriately chosen according to symptoms.

Claims

1. A pharmaceutical composition comprising a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
2. The pharmaceutical composition of claim 1, wherein said rapidly acting anti-inflammatory analgesic agent is a cyclooxygenase inhibitor.
3. The pharmaceutical composition of claim 1, wherein said rapidly acting anti-inflammatory analgesic agent is a central analgesic.
4. The pharmaceutical composition of claim 1, wherein said rapidly acting anti-inflammatory analgesic agent is a steroid.
5. The pharmaceutical composition of claim 1, wherein said rapidly acting anti-inflammatory analgesic agent is an anti-inflammatory enzyme agent.
6. The pharmaceutical composition of claim 1, wherein said quinoline or quinazoline compound for the prophylaxis or therapy of arthritis contains as an active ingredient a compound represented by the formula (I):
Figure imgf000050_0001
wherein Y represents a nitrogen atom or C-G (G represents a carboxyl group which may be esterified or amidated, an acyl, or a hydroxyalkyl group); R represents an optionally substituted hydrocarbon residue, or an optionally substituted heterocyclic group; X represents an oxygen atom or an optionally oxidized sulfur atom; n represents 0 or 1; k represents 0 or 1; G and R may bind together to form a ring; rings A and B may each have a substituent; or a pharmaceutically acceptable salt thereof.
7. The pharmaceutical composition of claim 6, wherein n represents 0 and the optionally substituted hydrocarbon residue for R is a group represented by the formula: -CH2-X1-Z1 , wherein X1 represents an oxygen atom, an optionally oxidized sulfur atom or -(CH2)m~ (m represents an integer from 0 to 5); Z1 represents an optionally substituted hydrocarbon residue, an optionally substituted heterocyclic group or an optionally substituted amino group.
8. The pharmaceutical composition of claim 7, wherein Xi is -(CH2)πι- (m is 0 or 1).
9. The pharmaceutical composition of claim 7, wherein the optionally substituted heterocyclic group for Z1 is an aromatic 5-membered heterocyclic group containing 2 or 3 hetero atoms.
10. The pharmaceutical composition of claim 6, wherein Y is C-G.
11. The pharmaceutical composition of claim 10, wherein G is a C s alkoxycarbonyl group.
12. The pharmaceutical composition of claim 10, wherein G is an ethoxycarbonyl group.
13. The pharmaceutical composition of claim 6, wherein ring A is substituted for by at least one alkoxy group.
14. The pharmaceutical composition of claim 6, wherein ring A is substituted for by two methoxy groups.
15. The pharmaceutical composition of claim 14, wherein ring A is substituted for by two methoxy groups respectively at the 6- and 7-positions of the quinoline ring or quinazoline ring.
16. The pharmaceutical composition of claim 6, wherein ring B is substituted for by at least one alkoxy group.
17. The pharmaceutical composition of claim 6, wherein ring B is substituted for by two identical or different alkoxy groups.
18. The pharmaceutical composition of claim 6, wherein k is 0.
19. The pharmaceutical composition of claim 6, wherein the compound represented by the formula (I) is methyl 4-(3,4-dimethoxyphenyl)-2-ethyl-6,7- dimethoxyquinoline-3-carboxylate; ethyl 6-chloro-2-methyl-4-(3,4- dimethoxyphenyl)quinoline-3-carboxylate;
6,7-dimethoxy-9-phenylfuro[3,4-b]quinoline-1(3H)-one; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (1- methylimidazol-2-yl)thiomethyl]quinoline-3-carboxylate;
4-(3,4-dimethoxyphenyl)-2-(2-hydroxyethylthiomethyl)- 6,7-dimethoxyquinazoline;
4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[ (4-methyl- 1,2,4-triazol-3-yl)thiomethyl]quinazoline; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-[2-(1- methylimidazol-2-yl)ethyl]quinoline-3-carboxylate; methyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-3- methoxycarbonylquinoline-2-acetate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3-isopropoxy-4-methoxyphenyl)-6,7-dimethoxy- 2-(1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 7-hydroxy-6-methoxy-4-(3,4-dimethoxyphenyl)-2- (1,2,4-triazol-l-ylmethyl)quinoline-3-carboxylate; ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-l-ylmethyl)quinoline-3-carboxylate 1-oxide; or ethyl 2-(N,N-diethylaminomethyl)-4-(3,4- dimethoxyphenyl)-6,7-dimethoxyquinoline-3-carboxylate.
20. A therapeutic agent for arthritis comprising a combination of a qunoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
21. A method of treating an arthritis and/or an inflammation in mammals which comprises administering to the mammals a therapeutically effective amount of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent.
22. The method according to claim 21, wherein the quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and the rapidly acting anti- inflammatory analgesic agent are administered simultaneously.
23. The method according to claim 21, wherein the quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and the rapidly acting anti- inflammatory analgesic agent are administered sequentially.
24. Use of a combination of a quinoline or quinazoline compound for the prophylaxis or therapy of arthritis and a rapidly acting anti-inflammatory analgesic agent to manufacture a preparation for treating an arthritis and/or an infllamation in mammals.
PCT/JP1996/001102 1995-04-28 1996-04-24 Therapeutic composition for arthritis Ceased WO1996033717A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP96912213A EP0830133A1 (en) 1995-04-28 1996-04-24 Therapeutic composition for arthritis
AU55136/96A AU715358B2 (en) 1995-04-28 1996-04-24 Therapeutic composition for arthritis
NO974956A NO974956D0 (en) 1995-04-28 1997-10-27 Therapeutic composition for arthritis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP7/106316 1995-04-28
JP10631695 1995-04-28
JP27085695 1995-10-19
JP7/270856 1995-10-19

Publications (1)

Publication Number Publication Date
WO1996033717A1 true WO1996033717A1 (en) 1996-10-31

Family

ID=26446436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/001102 Ceased WO1996033717A1 (en) 1995-04-28 1996-04-24 Therapeutic composition for arthritis

Country Status (7)

Country Link
EP (1) EP0830133A1 (en)
KR (1) KR19990008148A (en)
AU (1) AU715358B2 (en)
CA (1) CA2216138A1 (en)
HU (1) HUP9801628A2 (en)
NO (1) NO974956D0 (en)
WO (1) WO1996033717A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034115A1 (en) * 1997-02-04 1998-08-06 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
WO2002012192A1 (en) * 2000-08-09 2002-02-14 F. Hoffmann-La Roche Ag Quinolene derivatives as anti-inflammation agents
WO2002051442A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339485A1 (en) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0468789A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
EP0500360A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc. Quinoline-containing ketoacids as leukotriene antagonists
EP0567107A1 (en) * 1992-04-24 1993-10-27 Takeda Chemical Industries, Ltd. Quinoline and quinazoline derivatives for treating arthritis
EP0608870A1 (en) * 1993-01-28 1994-08-03 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives, their production and use
EP0686630A1 (en) * 1994-06-07 1995-12-13 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68908459T2 (en) * 1988-04-26 1994-04-07 Asahi Glass Co Ltd Prepolymer composition, process for its preparation and its use.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339485A1 (en) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
EP0468789A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
EP0500360A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc. Quinoline-containing ketoacids as leukotriene antagonists
EP0567107A1 (en) * 1992-04-24 1993-10-27 Takeda Chemical Industries, Ltd. Quinoline and quinazoline derivatives for treating arthritis
EP0608870A1 (en) * 1993-01-28 1994-08-03 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives, their production and use
EP0686630A1 (en) * 1994-06-07 1995-12-13 Takeda Chemical Industries, Ltd. Quinoline derivatives and pharmaceutical composition containing them

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034115A1 (en) * 1997-02-04 1998-08-06 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
WO2002012192A1 (en) * 2000-08-09 2002-02-14 F. Hoffmann-La Roche Ag Quinolene derivatives as anti-inflammation agents
US7049325B2 (en) 2000-08-09 2006-05-23 Syntex (U.S.A.) Llc Quinoline derivatives as anti-inflammatory agents
US7186840B2 (en) 2000-08-09 2007-03-06 Roche Palo Alto Llc Quinoline derivatives as anti-inflammatory agents
WO2002051442A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs

Also Published As

Publication number Publication date
HUP9801628A2 (en) 1999-01-28
AU715358B2 (en) 2000-01-20
EP0830133A1 (en) 1998-03-25
NO974956L (en) 1997-10-27
AU5513696A (en) 1996-11-18
NO974956D0 (en) 1997-10-27
CA2216138A1 (en) 1996-10-31
KR19990008148A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
KR102698413B1 (en) Heteroaromatic macrocyclic ether chemotherapeutic agent
TWI314867B (en) Reconstitutable parenteral composition
TWI230609B (en) Combination therapy for the treatment of cancer
WO2011149824A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
AU2012339679A1 (en) Combination therapy of Hsp90 inhibitors with BRAF inhibitors
WO2012039972A1 (en) Pharmaceutical composition
RS53717B1 (en) 1-aryl-3-aminoalkoxy pyrazoles as SIGMA ligands that increase the analgesic effect of opioids and reduce their dependence on them
US20030157061A1 (en) Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
WO2004096206A2 (en) Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
AU715358B2 (en) Therapeutic composition for arthritis
CN120303264A (en) CK1α and dual CK1α/GSPT1 degrading compounds
AU2003207453A2 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
EP1687001A2 (en) Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
CA2577664A1 (en) Novel heterocycles
KR20070059154A (en) Non-aqueous liquid parenteral aceclofenac preparations
JPH09169646A (en) Therapeutic agent for arthritis
AU6137396A (en) Immunosuppressant
AU758983B2 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
CA2576544A1 (en) Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194735.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1996 693223

Country of ref document: US

Date of ref document: 19960821

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 306554

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2216138

Country of ref document: CA

Ref document number: 2216138

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996912213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019970707673

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996912213

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970707673

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996912213

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970707673

Country of ref document: KR